{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:57:14Z","timestamp":1788868634090,"version":"build-2803163510"},"update-to":[{"DOI":"10.1002\/14651858.cd013539","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T00:00:00Z","timestamp":1732752000000}}],"reference-count":349,"publisher":"Wiley","issue":"11","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd013539.pub2","type":"journal-article","created":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T06:57:54Z","timestamp":1732777074000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Biosimilar monoclonal antibodies for cancer treatment in adults"],"prefix":"10.1002","volume":"2024","author":[{"given":"Tais F","family":"Galvao","sequence":"additional","affiliation":[{"name":"School of Pharmaceutical Sciences; Universidade Estadual de Campinas; Campinas Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemeri","family":"Livinalli","sequence":"additional","affiliation":[{"name":"School of Pharmaceutical Sciences; Universidade Estadual de Campinas; Campinas Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciane C","family":"Lopes","sequence":"additional","affiliation":[{"name":"Pharmaceutical Science Graduate Course; University of Sorocaba; Sorocaba Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan R","family":"Zimmermann","sequence":"additional","affiliation":[{"name":"Department of Public Health; University of Brasilia; Brasilia Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus Tolentino","family":"Silva","sequence":"additional","affiliation":[{"name":"Department of Public Health; University of Brasilia; Brasilia Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,11,28]]},"reference":[{"issue":"6","key":"10.1002\/14651858.CD013539.pub2-BIB0001|cit1","first-page":"55","article-title":"A prospective, randomized, multiple-dose, multi-center, comparative clinical study to evaluate the efficacy, safety, immunogenicity of a biosimilar bevacizumab (test product, Hetero) and reference medicinal product (bevacizumab, Roche) in patients of metastatic colorectal cancer","volume":"66","author":"Advani","year":"2018","journal-title":"Journal of the Association of Physicians of India"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0002|cit2","unstructured":"A prospective, randomized, multiple-dose, multi-center, comparative, parallel clinical study to evaluate the efficacy, safety, immunogenicity and pharmacokinetics of an intravenous infusion of bevacizumab (test product, hetero) and reference medicinal product (reference product, Roche) administered in combination with standard chemotherapy in patients of metastatic colorectal cancer ctri.nic.in\/Clinicaltrials\/pmaindet2.php?trialid=11692&EncHid=&userName=CTRI\/2015\/05\/005757"},{"issue":"3","key":"10.1002\/14651858.CD013539.pub2-BIB0003|cit3","doi-asserted-by":"publisher","first-page":"535","DOI":"10.4103\/ijc.IJC_394_17","article-title":"Comparative pharmacokinetics, efficacy, and safety of bevacizumab biosimilar to reference bevacizumab in patients with metastatic colorectal cancer","volume":"54","author":"Apsangikar","year":"2017","journal-title":"Indian Journal of Cancer"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0004|cit4","unstructured":"A clinical trial to study the effects of two drugs, R-TPR-023 and Avastin\u2122 in patients with metastatic colorectal cancer ctri.nic.in\/Clinicaltrials\/pmaindet2.php?trialid=5673&EncHid=&userName=CTRI\/2013\/05\/003699"},{"issue":"12","key":"10.1002\/14651858.CD013539.pub2-BIB0005|cit5","doi-asserted-by":"publisher","first-page":"20847","DOI":"10.1002\/cam4.6664","article-title":"Efficacy and safety of the proposed bevacizumab biosimilar BAT1706 compared with reference bevacizumab in patients with advanced nonsquamous non-small cell lung cancer: a randomized, double-blind, phase III study","volume":"22","author":"Chen","year":"2023","journal-title":"Cancer Medicine"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0006|cit6","doi-asserted-by":"crossref","unstructured":"Chen L Trukhin D Kolesnik O Rangel JD Cil T Li X Clinical efficacy and safety of the BAT1706 (proposed bevacizumab biosimilar) compared with reference bevacizumab in patients with advanced nonsquamous NSCLC: a randomized, double-blind, phase III study Journal of Clinical Oncology 2022 40 16 9041 10.1200\/JCO.2022.40.16","DOI":"10.1200\/JCO.2022.40.16_suppl.9041"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0007|cit7","unstructured":"A comparative study of BAT1706 and EU Avastin in patients with advanced non squamous non small cell lung cancer clinicaltrials.gov\/Ct2\/Show\/NCT03329911"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0008|cit8","unstructured":"Zhang A Dumas T Statistical Analysis Plan. BAT1706-003-CR. A multicenter, randomized, double blind, phase III study of BAT1706 versus EU AVASTIN\u00ae plus chemotherapy in patients with advanced non-squamous non-small cell lung cancer clinicaltrials.gov\/ct2\/show\/NCT03329911"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0009|cit9","unstructured":"Zhang L Clinical Study Protocol. BAT1706-003-CR. A multicenter, randomized, double blind, phase III study of BAT1706 versus EU AVASTIN\u00ae plus chemotherapy in patients with advanced non-squamous non-small cell lung cancer clinicaltrials.gov\/ct2\/show\/NCT03329911"},{"issue":"2","key":"10.1002\/14651858.CD013539.pub2-BIB0010|cit10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.20892\/j.issn.2095-3941.2020.0212","article-title":"Equivalent efficacy study of QL1101 and bevacizumab on untreated advanced non-squamous non-small cell lung cancer patients: a phase 3 randomized, double-blind clinical trial","volume":"18","author":"Chu","year":"2021","journal-title":"Cancer Biology & Medicine"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD013539.pub2-BIB0011|cit11","doi-asserted-by":"publisher","first-page":"ii62","DOI":"10.1093\/annonc\/mdz063.070","article-title":"A multi-center, randomized, double-blind, parallel, two-group phase III clinical study on the efficacy and safety of QL1101 or bevacizumab in combination with paclitaxel and carboplatin in the first-line treatment of non-squamous non-small cell lung cancer","volume":"30","author":"Han","year":"2019","journal-title":"Annals of Oncology"},{"issue":"Suppl 9","key":"10.1002\/14651858.CD013539.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"ix121","DOI":"10.1093\/annonc\/mdy442","article-title":"A multi-center, randomized, double-blind, parallel, two-group phase III trial on the efficacy and safety of QL1101 or bevacizumab in combination with paclitaxel and carboplatin in first-line treatment of non-squamous non-small cell lung cancer","volume":"29","author":"Han","year":"2018","journal-title":"Annals of Oncology"},{"issue":"10","key":"10.1002\/14651858.CD013539.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"S355","DOI":"10.1016\/j.jtho.2019.08.718","article-title":"P1.01-03 efficacy and safety of biosimilar QL1101 compared with Avastin in patients with non-squamous non-small cell lung cancer","volume":"14","author":"Han","year":"2019","journal-title":"Journal of Thoracic Oncology"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0014|cit14","unstructured":"A clinical trial to evaluate the pharmacokinetics, safety, efficacy and immunogenicity of Bmab-100 and Avastin in patients with metastatic colorectal cancer ctri.nic.in\/Clinicaltrials\/pmaindet2.php?trialid=5827&EncHid=&userName=Bmab-100"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0015|cit15","unstructured":"European Medicines Agency Assessment report of abevmy Committee for Medicinal Products for Human Use; 2021 February. Report N\u00ba EMA\/176217\/2021"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0016|cit16","unstructured":"A randomised double-blind study in two parts Part A \u2013 comparing two humanized monoclonal antibodies that target VEGF in combination with mFOLFOX6 in patients with non-resectable metastatic colorectal cancer (mCRC) and Part B \u2013 comparing two humanized monoclonal antibodies that target VEGF in combination with pemetrexed and carboplatin in recurrent or advanced nonsquamous non-small cell lung cancer (NSCLC) ctri.nic.in\/Clinicaltrials\/pmaindet2.php?EncHid=MTM2MDQ=&Enc=&userName=CTRI\/2016\/01\/006481"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0017|cit17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1055\/s-0043-1774403","article-title":"Comparison of efficacy and safety of a bevacizumab biosimilar, in combination with chemotherapies, in nonresectable metastatic colorectal cancer and in advanced nonsquamous non-small cell lung cancer: a randomized, double-blind, phase III study","volume":"EFirst","author":"Kasliwal","year":"2023","journal-title":"South Asian Journal of Cancer"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0018|cit18","unstructured":"A randomised double-blind study in two parts Part A \u2013 comparing two humanized monoclonal antibodies that target VEGF in combination with mFOLFOX6 in patients with non-resectable metastatic colorectal cancer (mCRC) and Part B \u2013 comparing two humanized monoclonal antibodies that target VEGF in combination with pemetrexed and carboplatin in recurrent or advanced nonsquamous non-small cell lung cancer (NSCLC) ctri.nic.in\/Clinicaltrials\/pmaindet2.php?EncHid=MTM2MDQ=&Enc=&userName=CTRI\/2016\/01\/006481"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0019|cit19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1055\/s-0043-1774403","article-title":"Comparison of efficacy and safety of a bevacizumab biosimilar, in combination with chemotherapies, in nonresectable metastatic colorectal cancer and in advanced nonsquamous non-small cell lung cancer: a randomized, double-blind, phase III study","volume":"EFirst","author":"Kasliwal","year":"2023","journal-title":"South Asian Journal of Cancer"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0020|cit20","unstructured":"Clinical study synopsis for public disclosure: INVICTAN study Mystudywindow.com\/trial\/completed\/89645\/1302-0005"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0021|cit21","unstructured":"Biosimilar study on lung cancer ctri.nic.in\/Clinicaltrials\/pdf_generate.php?trialid=14136&EncHid=&modid=&compid=%27,%2714136det%27"},{"issue":"1","key":"10.1002\/14651858.CD013539.pub2-BIB0022|cit22","doi-asserted-by":"publisher","first-page":"100248","DOI":"10.1016\/j.jtocrr.2021.100248","article-title":"Phase 3 trial of bi 695502 plus chemotherapy versus bevacizumab reference product plus chemotherapy in patients with advanced nonsquamous NSCLC","volume":"3","author":"Kim","year":"2022","journal-title":"Journal of Thoracic Oncology Clinical and Research Reports"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0023|cit23","unstructured":"Phase III trial bi 695502 plus chemotherapy vs Avastin\u00ae plus chemotherapy in patients with lung cancer clinicaltrials.gov\/ct2\/show\/NCT02272413"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"S1282","DOI":"10.1016\/j.annonc.2020.10.124","article-title":"104P Safety and efficacy of HLX04 versus reference bevacizumab in combination with XELOX or mFOLFOX6 as first-line treatment for metastatic colorectal cancer: a randomised, double-blind phase III study","volume":"31","author":"Qin","year":"2020","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0025|cit25","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s40259-021-00484-9","article-title":"Efficacy, safety, and immunogenicity of HLX04 versus reference bevacizumab in combination with XELOX or mFOLFOX6 as first-line treatment for metastatic colorectal cancer: results of a randomized, double-blind phase III study","volume":"35","author":"Qin","year":"2021","journal-title":"BioDrugs"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0026|cit26","unstructured":"A phase III, randomised, double-blind, multicentre study to compare the efficacy, safety, pharmacokinetics and immunogenicity between SB8 (proposed bevacizumab biosimilar) and Avastin\u00ae in subjects with metastatic or recurrent non-squamous non-small cell lung cancer clinicaltrialsregister.eu\/ctr-search\/trial\/2015-004026-34\/HU"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0027|cit27","unstructured":"European Medicines Agency Assessment report of aybintio Committee for Medicinal Products for Human Use; 2020 June. Report N\u00ba EMA\/380645\/2020"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0028|cit28","unstructured":"European Medicines Agency Assessment report of onbevzi Committee for Medicinal Products for Human Use; 2020 November. Report N\u00ba EMA\/117409\/2021"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0029|cit29","unstructured":"A study comparing SB8 and Avastin\u00ae in patients with advanced non-squamous non-small cell lung cancer clinicaltrials.gov\/ct2\/show\/NCT02754882"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0030|cit30","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.lungcan.2020.05.027","article-title":"A phase III, randomized, double-blind, multicenter study to compare the efficacy, safety, pharmacokinetics, and immunogenicity between SB8 (proposed bevacizumab biosimilar) and reference bevacizumab in patients with metastatic or recurrent nonsquamous non-small cell lung cancer","volume":"146","author":"Reck","year":"2020","journal-title":"Lung Cancer (Amsterdam, Netherlands)"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0031|cit31","unstructured":"European Medicines Agency Assessment report of zirabev Committee for Medicinal Products for Human Use; 2018 December. Report N\u00ba EMA\/97237\/2019"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0032|cit32","unstructured":"A comparative study of PF-06439535 plus paclitaxel-carboplatin and bevacizumab plus paclitaxel-carboplatin patients with advanced non-squamous non small cell lung cancer clinicaltrials.gov\/ct2\/show\/NCT02364999"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD013539.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"vi120","DOI":"10.1093\/annonc\/mdz343.010","article-title":"PF-06439535 (a bevacizumab biosimilar) for non-small cell lung cancer: subgroup analysis","volume":"30","author":"Okano","year":"2019","journal-title":"Annals of Oncology"},{"issue":"5","key":"10.1002\/14651858.CD013539.pub2-BIB0034|cit34","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s40259-019-00363-4","article-title":"PF-06439535 (a bevacizumab biosimilar) compared with reference bevacizumab (Avastin\u00ae), both plus paclitaxel and carboplatin, as first-line treatment for advanced non-squamous non-small-cell lung cancer: a randomized, double-blind study","volume":"33","author":"Reinmuth","year":"2019","journal-title":"BioDrugs"},{"issue":"Suppl 15","key":"10.1002\/14651858.CD013539.pub2-BIB0035|cit35","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1200\/JCO.2018.36.15_suppl.109","article-title":"A comparative clinical study of PF-06439535, a candidate bevacizumab biosimilar, and reference bevacizumab, in patients with advanced non-squamous non-small cell lung cancer","volume":"36","author":"Socinski","year":"2018","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0036|cit36","unstructured":"Comparing efficacy and safety of Stivant (aryogen bevacizumab) versus Avastin in metastatic colorectal cancer clinicaltrials.gov\/ct2\/show\/NCT03288987"},{"issue":"5","key":"10.1002\/14651858.CD013539.pub2-BIB0037|cit37","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/j.clinthera.2020.03.009","article-title":"Efficacy and safety of proposed bevacizumab biosimilar BE1040v in patients with metastatic colorectal cancer: a phase III, randomized, double-blind, noninferiority clinical trial","volume":"42","author":"Rezvani","year":"2020","journal-title":"Clinical Therapeutics"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0038|cit38","unstructured":"Bioequivalence study bevacizumab biosimilar (BEVZ92) versus bevacizumab (Avastin\u00ae) in first-line treatment mCRC patients clinicaltrials.gov\/show\/nct02069704"},{"issue":"Suppl 15","key":"10.1002\/14651858.CD013539.pub2-BIB0039|cit39","doi-asserted-by":"publisher","first-page":"e14065","DOI":"10.1200\/JCO.2017.35.15_suppl.e14065","article-title":"Results of bevacizumab biosimilar compared with RMP for the treatment of metastatic colorectal cancer","volume":"35","author":"Roca","year":"2017","journal-title":"Journal of Clinical Oncology"},{"issue":"12","key":"10.1002\/14651858.CD013539.pub2-BIB0040|cit40","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/S2468-1253(18)30269-3","article-title":"Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial","volume":"3","author":"Romera","year":"2018","journal-title":"Lancet Gastroenterology & Hepatology"},{"issue":"9","key":"10.1002\/14651858.CD013539.pub2-BIB0041|cit41","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1002\/cac2.12179","article-title":"Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first-line treatment for Chinese patients with unresectable, metastatic, or recurrent non-squamous non-small-cell lung cancer: a multicenter, randomized, double-blinded, phase III trial","volume":"41","author":"Shi","year":"2021","journal-title":"Cancer Communications"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0042|cit42","unstructured":"MYL-1402O compared with Avastin\u00ae, in patients with stage IV nsNSCLC clinicaltrials.gov\/ct2\/show\/results\/NCT04633564"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD013539.pub2-BIB0043|cit43","doi-asserted-by":"publisher","first-page":"S883","DOI":"10.1016\/j.annonc.2020.08.1705","article-title":"1391P Phase III confirmatory efficacy and safety study of proposed bevacizumab biosimilar (MYL-1402O) compared with Avastin, in the first-line treatment of patients with stage IV non-squamous non-small cell lung cancer (nsNSCLC)","volume":"31","author":"Socinski","year":"2020","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0044|cit44","doi-asserted-by":"publisher","first-page":"S1022","DOI":"10.1016\/j.annonc.2021.08.1939","article-title":"1338P A phase III study comparing BCD-021, a bevacizumab biosimilar, and reference bevacizumab in patients with stage IIIB or IV non-squamous NSCLC","volume":"32","author":"Fadeeva","year":"2021","journal-title":"Annals of Oncology"},{"issue":"Suppl 15","key":"10.1002\/14651858.CD013539.pub2-BIB0045|cit45","doi-asserted-by":"publisher","first-page":"8057","DOI":"10.1200\/jco.2015.33.15_suppl.8057","article-title":"Efficacy and safety of BCD-021, bevacizumab biosimilar candidate, compared to Avastin: results of international multicenter randomized double blind phase III study in patients with advanced non-squamous NSCLC","volume":"33","author":"Filon","year":"2015","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0046|cit46","unstructured":"A safety and efficacy study of BCD-021 with paclitaxel and carboplatin compared to Avastin with paclitaxel and carboplatin in non-small cell lung cancer clinicaltrials.gov\/ct2\/show\/NCT01763645"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0047|cit47","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s12885-022-09243-7","article-title":"Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-021 with reference bevacizumab","volume":"22","author":"Stroyakovskiy","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0048|cit48","unstructured":"Centus biotherapeutics clinical protocol no: FKB238-002. Study drug name: FKB238. A randomised, parallel, double blinded study to compare the efficacy and safety of FKB238 to Avastin\u00ae in 1st line treatment for patients with advanced\/recurrent non-squamous non-small cell lung cancer in combination of paclitaxel and carboplatin. (protocol version 5: 22 May 2018) Centus Biotherapeutics"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0049|cit49","unstructured":"European Medicines Agency Assessment report of equidacent Committee for Medicinal Products for Human Use; 2020 July. Report N\u00ba EMA\/427966\/2020"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0050|cit50","unstructured":"Evaluation of FKB238 and Avastin in patients with advanced \/ recurrent non-squamous non-small cell lung cancer (AVANA) clinicaltrials.gov\/ct2\/show\/NCT02810457"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0051|cit51","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s40259-021-00489-4","article-title":"Efficacy and safety of bevacizumab biosimilar FKB238 versus originator bevacizumab: results from AVANA, a phase III trial in patients with non-squamous non-small-cell lung cancer (non-sq-NSCLC)","volume":"35","author":"Syrigos","year":"2021","journal-title":"BioDrugs"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD013539.pub2-BIB0052|cit52","doi-asserted-by":"publisher","first-page":"e21728","DOI":"10.1200\/JCO.2020.38.15_suppl.e21728","article-title":"Efficacy and safety of bevacizumab biosimilar FKB238 versus originator bevacizumab: results from a phase III trial in patients with non-squamous non-small cell lung cancer (NS-NSCLC)","volume":"38","author":"Syrigos","year":"2020","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0053|cit53","unstructured":"A randomized, double-blind, phase 3 study evaluating the efficacy and safety of ABP 215 compared with bevacizumab in subjects with advanced non-small cell lung cancer Amgen; 2015 December. Clinical Study Report N\u00ba 20120265"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0054|cit54","unstructured":"A randomized, double-blind, phase 3 study evaluating the efficacy and safety of ABP215 compared with bevacizumab in subjects with advanced non-small cell lung cancer clinicaltrialsregister.eu\/ctr-search\/trial\/2013-000738-36\/results"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0055|cit55","unstructured":"European Medicines Agency Assessment report of mvasi Committee for Medicinal Products for Human Use; 2017 November. Report N\u00ba EMA\/798844\/2017"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0056|cit56","unstructured":"Efficacy and safety study of ABP 215 compared with bevacizumab in patients with advanced non-small cell lung cancer clinicaltrials.gov\/ct2\/show\/NCT01966003"},{"issue":"Suppl 10","key":"10.1002\/14651858.CD013539.pub2-BIB0057|cit57","doi-asserted-by":"publisher","first-page":"S814","DOI":"10.1016\/j.jtho.2018.08.1435","article-title":"P2.13-40 ABP 215 and bevacizumab in NSCLC patients: time course and magnitude of response in the phase 3 comparative trial (MAPLE)","volume":"13","author":"Thatcher","year":"2018","journal-title":"Journal of Thoracic Oncology"},{"issue":"7","key":"10.1002\/14651858.CD013539.pub2-BIB0058|cit58","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1158\/1078-0432.CCR-18-2702","article-title":"Efficacy and safety of the biosimilar ABP 215 compared with bevacizumab in patients with advanced nonsquamous non-small cell lung cancer (MAPLE): a randomized, double-blind, phase III study","volume":"25","author":"Thatcher","year":"2019","journal-title":"Clinical Cancer Research"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD013539.pub2-BIB0059|cit59","doi-asserted-by":"publisher","first-page":"vi414","DOI":"10.1093\/annonc\/mdw382.10","article-title":"Secondary efficacy results from a phase 3 study comparing efficacy and safety of biosimilar candidate ABP 215 with bevacizumab in patients with non-squamous non-small cell lung cancer (NSCLC)","volume":"27","author":"Thatcher","year":"2016","journal-title":"Annals of Oncology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013539.pub2-BIB0060|cit60","doi-asserted-by":"publisher","first-page":"S902","DOI":"10.1016\/j.jtho.2016.11.1234","article-title":"P2.03a-025 randomized, double-blind, phase 3 study comparing biosimilar candidate abp 215 with bevacizumab in patients with non-squamous NSCLC","volume":"12","author":"Thatcher","year":"2017","journal-title":"Journal of Thoracic Oncology"},{"issue":"Suppl 15","key":"10.1002\/14651858.CD013539.pub2-BIB0061|cit61","doi-asserted-by":"publisher","first-page":"9050","DOI":"10.1200\/JCO.2017.35.15_suppl.9050","article-title":"Clinical comparison of ABP 215 and bevacizumab in patients with NSCLC: pharmacokinetic results and justification for extrapolation across bevacizumab indications","volume":"35","author":"Thatcher","year":"2017","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013539.pub2-BIB0062|cit62","doi-asserted-by":"publisher","first-page":"9095","DOI":"10.1200\/JCO.2016.34.15_suppl.9095","article-title":"Randomized, double-blind, phase 3 study evaluating efficacy and safety of ABP 215 compared with bevacizumab in patients with non-squamous NSCLC","volume":"34","author":"Thatcher","year":"2016","journal-title":"Journal of Thoracic Oncology"},{"issue":"Suppl 15","key":"10.1002\/14651858.CD013539.pub2-BIB0063|cit63","doi-asserted-by":"publisher","first-page":"e20708","DOI":"10.1200\/JCO.2019.37.15_suppl.e20708","article-title":"Totality of evidence in development of the bevacizumab biosimilar ABP 215: central and investigator evaluation of efficacy from the MAPLE study","volume":"37","author":"Thomas","year":"2019","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0064|cit64","unstructured":"Study to assess the efficacy and safety of MB02 (bevacizumab biosimilar drug) versus Avastin\u00ae in combination with carboplatin and paclitaxel for the treatment of subjects with stage IIIb \/ IV non-squamous non-small cell lung cancer (NSCLC) https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=2017-001769-26"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0065|cit65","unstructured":"European Medicines Agency Assessment report of alymsys Committee for Medicinal Products for Human Use; 2021 January. Report N\u00ba EMA\/112177\/2021"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0066|cit66","unstructured":"European Medicines Agency Assessment report of oyavas Committee for Medicinal Products for Human Use; 2021 January. Report N\u00ba EMA\/112177\/2021"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0067|cit67","unstructured":"A randomized, multicenter, multinational, double-blind study to assess the efficacy and safety of MB02 (bevacizumab biosimilar drug) versus Avastin\u00ae in combination with carboplatin and paclitaxel for the treatment of subjects with stage IIIb\/IV non-squamous non-small cell lung cancer (NSCLC) lbctr.moph.gov.lb\/Trials\/Details\/4538"},{"issue":"Suppl 15","key":"10.1002\/14651858.CD013539.pub2-BIB0068|cit68","doi-asserted-by":"publisher","first-page":"e21542","DOI":"10.1200\/JCO.2020.38.15_suppl.e21542","article-title":"Bevacizumab biosimilar and reference bevacizumab in subjects with stage IIIB\/IV no squamous non-small cell lung cancer (NSCLC) (STELLA study): results for the primary endpoint in a confirmatory, double-blind, randomized, controlled study","volume":"38","author":"Millan","year":"2020","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0069|cit69","unstructured":"A study comparing MB02 and Avastin\u00ae in subjects with stage IIIB \/ IV non-squamous non- small cell lung cancer (NSCLC) (STELLA) clinicaltrials.gov\/ct2\/show\/NCT03296163"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0070|cit70","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s40259-021-00483-w","article-title":"Efficacy, safety and immunogenicity of mb02 (bevacizumab biosimilar) versus reference bevacizumab in advanced non-small cell lung cancer: a randomized, double-blind, phase III study (STELLA)","volume":"35","author":"Trukhin","year":"2021","journal-title":"BioDrugs"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0071|cit71","unstructured":"European Medicines Agency Assessment report of abevmy Committee for Medicinal Products for Human Use; 2022 June. Report N\u00ba EMA\/636045\/2022"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0072|cit72","unstructured":"To compare efficacy and safety of CT-P16 and EU-approved Avastin as first-line treatment for metastatic or recurrent non-squamous non-small cell lung cancer clinicaltrials.gov\/ct2\/show\/NCT03676192"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0073|cit73","doi-asserted-by":"publisher","first-page":"CT551","DOI":"10.1158\/1538-7445.AM2022-CT551","article-title":"Abstract CT551: randomized phase III study comparing the efficacy and safety of CT-P16, a new biosimilar, to reference bevacizumab (Avastin\u00ae) in patients with metastatic or recurrent non-small cell lung cancer (NSCLC)","volume":"Suppl 12","author":"Ohe","year":"2022","journal-title":"Cancer Research"},{"issue":"S7","key":"10.1002\/14651858.CD013539.pub2-BIB0074|cit74","doi-asserted-by":"publisher","first-page":"S1024","DOI":"10.1016\/j.annonc.2022.07.1153","article-title":"1-year follow-up of a phase III study to compare efficacy and safety of a bevacizumab biosimilar, CT-P16, and reference bevacizumab as first-line treatment for metastatic or recurrent non-squamous non-small cell lung cancer","volume":"33","author":"Verschraegen","year":"2022","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0075|cit75","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1007\/s40259-022-00552-8","article-title":"Candidate bevacizumab biosimilar CT-P16 versus European Union reference bevacizumab in patients with metastatic or recurrent non-small cell lung cancer: a randomized controlled trial","volume":"36","author":"Verschraegen","year":"2022","journal-title":"BioDrugs"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0076|cit76","doi-asserted-by":"publisher","first-page":"S1023","DOI":"10.1016\/j.annonc.2021.08.1940","article-title":"1339P Efficacy and safety of MIL60, a bevacizumab biosimilar, in combination with paclitaxel\/carboplatin in patients with advanced or recurrent non-squamous non-small cell lung cancer: a randomized, double-blind, multicenter phase III study","volume":"32","author":"Wang","year":"2021","journal-title":"Annals of Oncology"},{"issue":"6","key":"10.1002\/14651858.CD013539.pub2-BIB0077|cit77","doi-asserted-by":"publisher","first-page":"989","DOI":"10.21037\/tlcr.2019.12.23","article-title":"Biosimilar candidate IBI305 plus paclitaxel\/carboplatin for the treatment of non-squamous non-small cell lung cancer","volume":"8","author":"Yang","year":"2019","journal-title":"Translational Lung Cancer Research"},{"issue":"Suppl 15","key":"10.1002\/14651858.CD013539.pub2-BIB0078|cit78","doi-asserted-by":"publisher","first-page":"9095","DOI":"10.1200\/JCO.2019.37.15_suppl.9095","article-title":"Efficacy and safety of IBI305 compared with bevacizumab in advanced non-squamous NSCLC patients as first-line treatment in a randomized, double-blind, phase III study","volume":"37","author":"Zhang","year":"2019","journal-title":"Journal of Clinical Oncology"},{"issue":"9","key":"10.1002\/14651858.CD013539.pub2-BIB0079|cit79","doi-asserted-by":"publisher","first-page":"5907","DOI":"10.1007\/s00432-022-04563-4","article-title":"Bevacizumab biosimilar candidate TAB008 compared to Avastin\u00ae in patients with locally advanced, metastatic EGFR wild-type non-squamous non-small cell lung cancer: a randomized, double-blind, multicenter study","volume":"149","author":"Lu","year":"2023","journal-title":"Journal of Cancer Research and Clinical Oncology"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0080|cit80","unstructured":"TAB008 compared to Avastin\u00ae in patients with EGFR wild-type non-squamous non-small cell lung cancer clinicaltrials.gov\/ct2\/show\/NCT05427305"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD013539.pub2-BIB0081|cit81","doi-asserted-by":"publisher","first-page":"S1393","DOI":"10.1016\/j.annonc.2020.10.382","article-title":"388P biosimilar TAB008 compared with bevacizumab in advanced non-squamous, non-small cell, EGFR wildtype lung cancer patients","volume":"31","author":"Zhou","year":"2020","journal-title":"Annals of Oncology"},{"issue":"3","key":"10.1002\/14651858.CD013539.pub2-BIB0082|cit82","doi-asserted-by":"publisher","first-page":"316","DOI":"10.4103\/ijmpo.ijmpo_25_17","article-title":"A randomized, multiple-dose, multicenter, comparative parallel study to evaluate the safety and efficacy of intravenous infusion of rituximab (Hetero) and reference medicinal product (rituximab, Roche) in Indian patients of non-Hodgkin's lymphoma (HERILY)","volume":"39","author":"Advani","year":"2018","journal-title":"Indian Journal of Medical and Paediatric Oncology"},{"issue":"October","key":"10.1002\/14651858.CD013539.pub2-BIB0083|cit83","first-page":"58","article-title":"Efficacy, safety and immunogenecity study of intravenous infusion of rituximab (Hetero) and reference medicinal product (rituximab, Roche) in Indian patients of follicular lymphoma preliminary report (HERILY)","volume":"65","author":"Advani","year":"2017","journal-title":"Journal of Association of Physicians of India"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0084|cit84","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1002\/hon.2438_83","article-title":"A double-blind, randomized phase 3 study to compare efficacy and safety of CT-P10 to rituximab in combination with CVP in patients with advanced-stage follicular lymphoma","volume":"35","author":"Buske","year":"2017","journal-title":"Hematological Oncology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013539.pub2-BIB0085|cit85","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1182\/blood-2019-126379","article-title":"Long-term efficacy and safety results of CT-P10 and reference rituximab in patients with newly diagnosed advanced stage follicular lymphoma: phase III updated study results with median follow-up of 40 months","volume":"134","author":"Buske","year":"2019","journal-title":"Blood"},{"issue":"22","key":"10.1002\/14651858.CD013539.pub2-BIB0086|cit86","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1182\/blood.V128.22.1807.1807","article-title":"Pharmacokinetic and safety of CT-P10, a biosimilar candidate to the rituximab reference product, in patients with newly diagnosed advanced stage follicular lymphoma (AFL)","volume":"128","author":"Coiffier","year":"2016","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013539.pub2-BIB0087|cit87","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1182\/blood-2018-99-112716","article-title":"Similar efficacy and safety of CT-P10 and reference rituximab in patients with advanced stage follicular lymphoma: updated phase III study results","volume":"132","author":"Buske","year":"2018","journal-title":"Blood"},{"issue":"Suppl 15","key":"10.1002\/14651858.CD013539.pub2-BIB0088|cit88","doi-asserted-by":"publisher","first-page":"7532","DOI":"10.1200\/JCO.2017.35.15_suppl.7532","article-title":"Double-blind, randomized phase 3 study to compare efficacy and safety of the biosimilar CT-P10 to rituximab combined with CVP therapy in patients with previously untreated advanced-stage follicular lymphoma","volume":"35","author":"Jurczak","year":"2017","journal-title":"Journal of Clinical Oncology"},{"issue":"8","key":"10.1002\/14651858.CD013539.pub2-BIB0089|cit89","doi-asserted-by":"publisher","first-page":"e362","DOI":"10.1016\/S2352-3026(17)30120-5","article-title":"Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial","volume":"4","author":"Kim","year":"2017","journal-title":"Lancet Haematology"},{"issue":"Suppl 10","key":"10.1002\/14651858.CD013539.pub2-BIB0090|cit90","doi-asserted-by":"publisher","first-page":"x94","DOI":"10.1093\/annonc\/mdx664.001","article-title":"CT-P10 versus reference rituximab in combination with CVP in advanced-stage follicular lymphoma: phase 3, double-blind, randomized trial","volume":"28","author":"Kim","year":"2017","journal-title":"Annals of Oncology"},{"issue":"23","key":"10.1002\/14651858.CD013539.pub2-BIB0091|cit91","doi-asserted-by":"publisher","first-page":"5111","DOI":"10.1182\/blood.V126.23.5111.5111","article-title":"Global phase I\/III pharmacokinetic and efficacy study comparing CT-P10, a biosimilar candidate to the rituximab reference product in patients with advanced stage follicular lymphoma (AFL)","volume":"126","author":"Kim","year":"2015","journal-title":"Blood"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0092|cit92","first-page":"250","article-title":"A double-blind, randomized phase 3 study to compare efficacy and safety of CT-P10 to innovator rituximab in combination with CVP in patients with previously untreated advanced follicular lymphoma","volume":"102","author":"Ogura","year":"2017","journal-title":"Haematologica"},{"issue":"3","key":"10.1002\/14651858.CD013539.pub2-BIB0093|cit93","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s00280-018-3524-9","article-title":"Comparative assessment of pharmacokinetics, and pharmacodynamics between RTXM83\u2122, a rituximab biosimilar, and rituximab in diffuse large B-cell lymphoma patients: a population PK model approach","volume":"81","author":"Candelaria","year":"2018","journal-title":"Cancer Chemotherapy and Pharmacology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013539.pub2-BIB0094|cit94","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1182\/blood.V130.Suppl_1.1556.1556","article-title":"A randomized, double-blind, phase III study comparing proposed biosimilar rituximab (RTXM83) versus reference rituximab, both in combination with CHOP, in the first line treatment of patients with diffuse large B-cell lymphoma (DLBCL)","volume":"130","author":"Candelaria","year":"2017","journal-title":"Blood"},{"issue":"14","key":"10.1002\/14651858.CD013539.pub2-BIB0095|cit95","doi-asserted-by":"publisher","first-page":"3375","DOI":"10.1080\/10428194.2019.1633632","article-title":"Rituximab biosimilar RTXM83 versus reference rituximab in combination with CHOP as first-line treatment for diffuse large B-cell lymphoma: a randomized, double-blind study","volume":"60","author":"Candelaria","year":"2019","journal-title":"Leukemia & Lymphoma"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0096|cit96","unstructured":"Study of RTXM83 plus CHOP chemotherapy versus a rituximab plus CHOP therapy in patients with non Hodgkin's lymphoma clinicaltrials.gov\/ct2\/show\/NCT02268045"},{"issue":"1","key":"10.1002\/14651858.CD013539.pub2-BIB0097|cit97","doi-asserted-by":"publisher","first-page":"11676","DOI":"10.1038\/s41598-020-68360-0","article-title":"Pharmacokinetics and safety of IBI301 versus rituximab in patients with CD20+ B-cell lymphoma: a multicenter, randomized, double-blind, parallel-controlled study","volume":"10","author":"Jiang","year":"2020","journal-title":"Scientific Reports"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0098|cit98","unstructured":"A study to assess the pharmacokinetics and safety of recombinant human murine chimeric anti CD20 monoclonal antibody injection (IBI301) compared to rituximab injection in CD20 positive B cell lymphoma patients clinicaltrials.gov\/ct2\/show\/NCT02945215"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0099|cit99","unstructured":"A randomized, controlled, double-blind phase III trial to compare the efficacy, safety and pharmacokinetics of GP2013 plus MabThera\u00ae maintenance therapy in patients with previously untreated, advanced stage follicular lymphoma https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=2010-019522-13"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0100|cit100","unstructured":"European Medicines Agency Assessment report: rixathon https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/rixathon-epar-public-assessment-report_en.pdf"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0101|cit101","unstructured":"European Medicines Agency Assessment report: riximyo https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/riximyo-epar-public-assessment-report_en.pdf"},{"issue":"22","key":"10.1002\/14651858.CD013539.pub2-BIB0102|cit102","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1182\/blood.V128.22.1809.1809","article-title":"A phase III efficacy and safety study of the proposed rituximab biosimilar GP2013 versus rituximab in patients with previously untreated advanced follicular lymphoma","volume":"128","author":"Jurczak","year":"2016","journal-title":"Blood"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0103|cit103","doi-asserted-by":"publisher","first-page":"v355","DOI":"10.1093\/annonc\/mdx373","article-title":"Equivalent efficacy of a biosimilar rituximab and reference rituximab in previously untreated advanced follicular lymphoma: extended results of ASSIST-FL, a confirmatory phase III study","volume":"28","author":"Jurczak","year":"2017","journal-title":"Annals of Oncology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013539.pub2-BIB0104|cit104","first-page":"62","article-title":"A phase III efficacy and safety study of the proposed rituximab biosimilar GP2013 versus rituximab in 629 patients with previously untreated advanced follicular lymphoma","volume":"176","author":"Jurczak","year":"2017","journal-title":"British Journal of Haematology"},{"issue":"8","key":"10.1002\/14651858.CD013539.pub2-BIB0105|cit105","doi-asserted-by":"publisher","first-page":"e350","DOI":"10.1016\/S2352-3026(17)30106-0","article-title":"Rituximab biosimilar and reference rituximab in patients with previously untreated advanced follicular lymphoma (ASSIST-FL): primary results from a confirmatory phase 3, double-blind, randomised, controlled study","volume":"4","author":"Jurczak","year":"2017","journal-title":"Lancet Haematology"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0106|cit106","unstructured":"Protocol number AGB 002. A randomized, double-blind, multi-center, multinational trial to evaluate the efficacy, safety, and immunogenicity of SAIT101 versus rituximab as a first-line immunotherapy treatment in patients with low tumor burden follicular lymphoma Archigen Biotech Limited 116"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0107|cit107","unstructured":"A randomized, double-blind, multi-center, multi-national trial to evaluate the efficacy, safety, and immunogenicity of SAIT101 versus rituximab as a first-line immunotherapy treatment in patients with low tumor burden follicular lymphoma https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=2016-001966-27"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013539.pub2-BIB0108|cit108","first-page":"317","article-title":"Safety, pharmacokinetic\/pharmacodynamic profiles and efficacy of SAIT101, a biosimilar of rituximab in patients with diffuse large B-cell lymphoma","volume":"12","author":"Kim","year":"2012","journal-title":"Haematologica"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0109|cit109","unstructured":"A randomized, double-blind, multi-center, multi-national trial to evaluate the efficacy, safety, and immunogenicity of SAIT101 versus rituximab as a first-line immunotherapy treatment in patients with low tumor burden follicular lymphoma clinicaltrials.gov\/show\/nct02809053"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0110|cit110","unstructured":"Clinical study protocol Randomized, parallel-group, double-blind, comparative bioequivalence trial of MABIONCD20 (MABION SA) compared to MabThera (rituximab by Hoffman-la Roche) in patients with diffuse large B-cell lymphoma classic.clinicaltrials.gov\/ProvidedDocs\/85\/NCT02617485\/Prot_000.pdf"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0111|cit111","unstructured":"Randomized, parallel-group, double-blind, comparative bioequivalence trial of MabionCD20 (Mabion S.A) compared to MabThera (rituximab by Hoffman-La Roche) in patients with diffuse large B-cell Lymphoma clinicaltrialsregister.eu\/ctr-search\/search?query=2013-005506-56"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0112|cit112","unstructured":"MabionCD20\u00ae compared to MabThera\u00ae in lymphoma patients (MADILYM) clinicaltrials.gov\/ct2\/show\/study\/NCT02617485"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0113|cit113","unstructured":"Clinical study protocol A randomised, double-blind, parallel-group, phase III study to compare the efficacy, safety, and immunogenicity of proposed rituximab biosimilar (DRL_RI) with MabThera\u00ae in subjects with previously untreated, stage II-IV, cluster of differentiation (CD)20-positive, low tumour burden follicular lymphoma (protocol number: ri-01-006) cdn.clinicaltrials.gov\/large-docs\/02\/NCT03976102\/Prot_000.pdf"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0114|cit114","unstructured":"A randomised, double-blind, parallel-group, phase III study to compare the efficacy, safety, and immunogenicity of proposed rituximab biosimilar (DRL_RI) with MabThera\u00ae in subjects with previously untreated (CD)20-positive ltb follicular lymphoma clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2018-004223-36"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0115|cit115","unstructured":"A double-blind, parallel-group, phase III study to compare the efficacy, safety, and immunogenicity of proposed rituximab biosimilar (DRL_RI) with MabThera\u00ae in subjects with previously untreated (CD)20-positive LTB follicular lymphoma clinicaltrials.gov\/ct2\/show\/NCT03976102"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0116|cit116","unstructured":"Clinical study report 20130109: ABP 798 https:\/\/www.amgentrials.com\/"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0117|cit117","unstructured":"Center for Drug Evaluation and Research Multi-discipline review: riabni https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0118|cit118","doi-asserted-by":"crossref","unstructured":"Niederwieser D Hamm C Cobb P Mo M Forsyth C Tucci A Efficacy and safety of ABP 798 compared with rituximab: results from the comparative clinical study in patients with non-Hodgkin's lymphoma European Hematology Association. EHA 25 Virtual European Hematology Association 2020","DOI":"10.1200\/JCO.2020.38.15_suppl.8044"},{"issue":"5","key":"10.1002\/14651858.CD013539.pub2-BIB0119|cit119","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s11523-020-00748-4","article-title":"Efficacy and safety of ABP 798: results from the jasmine trial in patients with follicular lymphoma in comparison with rituximab reference product","volume":"15","author":"Niederwieser","year":"2020","journal-title":"Targeted Oncology"},{"issue":"Suppl 15","key":"10.1002\/14651858.CD013539.pub2-BIB0120|cit120","doi-asserted-by":"publisher","first-page":"8044","DOI":"10.1200\/JCO.2020.38.15_suppl.8044","article-title":"Efficacy and safety of ABP 798 compared with rituximab: results from the comparative clinical study in patients with non-Hodgkin's","volume":"38","author":"Niederwieser","year":"2020","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0121|cit121","unstructured":"European Medicines Agency Assessment report: Truxima https:\/\/ema.europa.eu\/en\/documents\/assessment-report\/truxima-epar-public-assessment-report_en.pdf"},{"issue":"2","key":"10.1002\/14651858.CD013539.pub2-BIB0122|cit122","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.clml.2021.08.005","article-title":"Efficacy and safety of CT-P10 versus rituximab in untreated low-tumor-burden follicular lymphoma: final results of a randomized phase III study","volume":"22","author":"Kwak","year":"2022","journal-title":"Clinical Lymphoma, Myeloma & Leukemia"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0123|cit123","unstructured":"To compare efficacy and safety between CT-P10 and Rituxan in patients with low tumour burden follicular lymphoma clinicaltrials.gov\/ct2\/show\/NCT02260804"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013539.pub2-BIB0124|cit124","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1182\/blood-2018-99-110334","article-title":"Comparison of efficacy and safety of biosimilar CT-P10 to rituximab in patients with previously untreated low tumor burden follicular lymphoma (LTBFL): a randomized phase III study","volume":"132","author":"Ogura","year":"2018","journal-title":"Blood"},{"issue":"11","key":"10.1002\/14651858.CD013539.pub2-BIB0125|cit125","doi-asserted-by":"publisher","first-page":"e543","DOI":"10.1016\/S2352-3026(18)30157-1","article-title":"Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial","volume":"5","author":"Ogura","year":"2018","journal-title":"Lancet Haematology"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0126|cit126","unstructured":"Randomized, assessor-blind, multicentre, parallel group, two arms, clinical study to assess the efficacy, pharmacokinetics, pharmacodynamics, immunogenicity and safety of rituximab (test product, Zydus) in comparison with rituximab (reference product, Roche\/Genentech) in patients with diffuse large B cell lymphoma (DLBCL) ctri.nic.in\/Clinicaltrials\/pmaindet2.php?EncHid=MjY4MTM=&Enc=&userName=CTRI\/2018\/07\/014885"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0127|cit127","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s00280-023-04530-x","article-title":"Rituximab biosimilar for the treatment of diffuse large B-cell lymphoma: a phase 3 randomized study in India","volume":"91","author":"Patel","year":"2023","journal-title":"Cancer Chemotherapy and Pharmacology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013539.pub2-BIB0128|cit128","first-page":"144","article-title":"Clinical comparability of BCD-020 to innovator rituximab in patients with indolent non-Hodgkin's lymphoma","volume":"99","author":"Alexeev","year":"2014","journal-title":"Haematologica"},{"issue":"21","key":"10.1002\/14651858.CD013539.pub2-BIB0129|cit129","doi-asserted-by":"publisher","first-page":"5467","DOI":"10.1182\/blood.V124.21.5467.5467","article-title":"Key results of international randomized open-label clinical study of BCD-020 (rituximab biosimilar candidate) in patients with B-cell non-Hodgkin's lymphoma","volume":"124","author":"Kaplanov","year":"2014","journal-title":"Blood"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0130|cit130","unstructured":"Safety and efficacy study of BCD-020 in therapy of indolent non-Hodgkin's lymphoma clinicaltrials.gov\/ct2\/show\/NCT01701232"},{"issue":"Suppl 15","key":"10.1002\/14651858.CD013539.pub2-BIB0131|cit131","doi-asserted-by":"publisher","first-page":"e19545","DOI":"10.1200\/jco.2014.32.15_suppl.e19545","article-title":"Comparison of pharmacokinetics and pharmacodynamics of BCD-020 with innovator rituximab in patients with indolent non-Hodgkin lymphoma","volume":"32","author":"Poddubnaya","year":"2014","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD013539.pub2-BIB0132|cit132","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/hon.2693","article-title":"Proposed rituximab biosimilar BCD-020 versus reference rituximab for treatment of patients with indolent non-Hodgkin lymphomas: an international multicenter randomized trial","volume":"38","author":"Poddubnaya","year":"2020","journal-title":"Hematological Oncology"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0133|cit133","unstructured":"European Medicines Agency Assessment report: ruxience https:\/\/ema.europa.eu\/en\/documents\/assessment-report\/ruxience-epar-public-assessment-report_en.pdf"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0134|cit134","unstructured":"A study of PF-05280586 (rituximab-Pfizer) or MabThera\u00ae (rituximab-EU) for the first-line treatment of patients with CD20-positive, low tumor burden, follicular lymphoma (reflections b328-06) clinicaltrials.gov\/ct2\/show\/NCT02213263"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013539.pub2-BIB0135|cit135","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1182\/blood-2018-99-111248","article-title":"A randomized, double-blind efficacy and safety study of PF-05280586 (a potential rituximab biosimilar) compared with rituximab reference product (MabThera\u00ae) in subjects with previously untreated CD20-positive, low tumor burden follicular lymphoma (LTB-FL)","volume":"132","author":"Sharman","year":"2018","journal-title":"Blood"},{"issue":"2","key":"10.1002\/14651858.CD013539.pub2-BIB0136|cit136","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s40259-019-00398-7","article-title":"A randomized, double-blind, efficacy and safety study of PF-05280586 (a rituximab biosimilar) compared with rituximab reference product (MabThera\u00ae) in subjects with previously untreated CD20-positive, low-tumor-burden follicular lymphoma (LTB-FL)","volume":"34","author":"Sharman","year":"2020","journal-title":"BioDrugs"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0137|cit137","unstructured":"Clinical study to compare the efficacy and safety of rituximab biosimilar HLX01 and rituximab in combination with CHOP, in previously untreated subjects with CD20+ DLBCL clinicaltrials.gov\/ct2\/show\/study\/NCT02787239"},{"issue":"124","key":"10.1002\/14651858.CD013539.pub2-BIB0138|cit138","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-024-11876-9","article-title":"Long-term outcomes with HLX01(HanliKang\u00ae), a rituximab biosimilar, in previously untreated patients with diffuse large B-cell lymphoma: 5-year follow-up results of the phase 3 HLX01-NHL03 study","volume":"24","author":"Qin","year":"2024","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1002\/14651858.CD013539.pub2-BIB0139|cit139","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13045-020-00871-9","article-title":"A phase 3 study of rituximab biosimilar HLX01 in patients with diffuse large B-cell lymphoma","volume":"13","author":"Shi","year":"2020","journal-title":"Journal of Hematology & Oncology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013539.pub2-BIB0140|cit140","doi-asserted-by":"publisher","first-page":"2878","DOI":"10.1182\/blood-2019-130603","article-title":"First China approved rituximab biosimilar HLX01: pharmacokinetics, safety and efficacy comparison to reference rituximab in the phase 3 diffuse large B-cell lymphoma study","volume":"134","author":"Shi","year":"2019","journal-title":"Blood"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0141|cit141","doi-asserted-by":"publisher","first-page":"ix88","DOI":"10.1093\/annonc\/mdy437.005","article-title":"First China-manufactured proposed rituximab biosimilar met primary efficacy and safety endpoints in CD20-positive diffuse large B-cell lymphoma (generics)","volume":"29","author":"Shi","year":"2018","journal-title":"Annals of Oncology"},{"issue":"4","key":"10.1002\/14651858.CD013539.pub2-BIB0142|cit142","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1007\/s12325-020-01603-8","article-title":"Efficacy and safety of the biosimilar IBI301 plus standard CHOP (I-CHOP) in comparison with rituximab plus CHOP (R-CHOP) in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): a randomized, double-blind, parallel-group, phase 3 trial","volume":"38","author":"Song","year":"2021","journal-title":"Advances in Therapy"},{"issue":"2","key":"10.1002\/14651858.CD013539.pub2-BIB0143|cit143","first-page":"84","article-title":"A double-blind, randomized comparison study between Zytux\u2122 vs MabThera\u00ae in treatment of CLL with FCR regimen: non-inferiority clinical trial","volume":"12","author":"Toogeh","year":"2018","journal-title":"International Journal of Hematology-Oncology and Stem Cell Research"},{"issue":"Suppl 15","key":"10.1002\/14651858.CD013539.pub2-BIB0144|cit144","doi-asserted-by":"publisher","first-page":"7550","DOI":"10.1200\/JCO.2017.35.15_suppl.7550","article-title":"Comparative double-blind randomized trial of 2 rituximab products in patients with CD20+ diffuse large B-cell lymphoma (DLBCL)","volume":"35","author":"Shah","year":"2017","journal-title":"Journal of Clinical Oncology"},{"issue":"22","key":"10.1002\/14651858.CD013539.pub2-BIB0145|cit145","doi-asserted-by":"publisher","first-page":"5391","DOI":"10.1182\/blood.V128.22.5391.5391","article-title":"Comparison of pharmacokinetics and pharmacodynamics of two anti-CD20 monoclonal antibodies (candidate biosimilar DRL-rituximab and innovator reference product rituximab (MabThera\u00ae)) in a randomised, multi-centre, double-blind, parallel group study of CHOP","volume":"128","author":"Viswabandya","year":"2016","journal-title":"Blood"},{"issue":"5","key":"10.1002\/14651858.CD013539.pub2-BIB0146|cit146","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JGO.19.00248","article-title":"Randomized, double-blind, pharmacokinetic equivalence trial comparing DRL-rituximab with MabThera in patients with diffuse large B-cell lymphoma","volume":"2019","author":"Viswabandya","year":"2019","journal-title":"Journal of Global Oncology"},{"issue":"1","key":"10.1002\/14651858.CD013539.pub2-BIB0147|cit147","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1186\/s12885-020-07247-9","article-title":"Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-022 with reference trastuzumab","volume":"20","author":"Alexeev","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0148|cit148","unstructured":"A safety and efficacy study of BCD-022 with paclitaxel compared to Herceptin with paclitaxel in HER2-positive metastatic breast cancer patients clinicaltrials.gov\/ct2\/show\/NCT01764022"},{"issue":"4","key":"10.1002\/14651858.CD013539.pub2-BIB0149|cit149","doi-asserted-by":"publisher","first-page":"664","DOI":"10.4103\/ijc.IJC_449_17","article-title":"A comparative phase III clinical study to evaluate efficacy and safety of TrastuRel\u2122 (biosimilar trastuzumab) and innovator trastuzumab in patients with metastatic human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer","volume":"54","author":"Apsangikar","year":"2017","journal-title":"Indian Journal of Cancer"},{"issue":"4","key":"10.1002\/14651858.CD013539.pub2-BIB0150|cit150","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s00280-019-03920-4","article-title":"Efficacy and safety of CT-P6 versus reference trastuzumab in HER2-positive early breast cancer: updated results of a randomised phase 3 trial","volume":"84","author":"Esteva","year":"2019","journal-title":"Cancer Chemotherapy and Pharmacology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD013539.pub2-BIB0151|cit151","doi-asserted-by":"publisher","first-page":"P5","DOI":"10.1158\/1538-7445.SABCS17-P5-20-14","article-title":"Abstract P5-20-14: cardiotoxicity in 1 year of treatment with reference trastuzumab and its biosimilar candidate CT-P6 in HER2 positive early stage breast cancer (EBC) patients","volume":"78","author":"Esteva","year":"2018","journal-title":"Cancer Research"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD013539.pub2-BIB0152|cit152","doi-asserted-by":"publisher","first-page":"P6","DOI":"10.1158\/1538-7445.SABCS18-P6-17-03","article-title":"P6-17-03: 24 months results from a double-blind, randomized phase III trial comparing the efficacy and safety of neoadjuvant then adjuvant trastuzumab and its biosimilar candidate CT-P6 in HER2 positive early breast cancer (EBC)","volume":"79","author":"Esteva","year":"2019","journal-title":"Cancer Research"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0153|cit153","unstructured":"European Medicines Agency Assessment report of herzuma https:\/\/ema.europa.eu\/en\/documents\/assessment-report\/herzuma-epar-public-assessment-report_en.pdf"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0154|cit154","unstructured":"Efficacy and safety evaluating study of CT-P6 in HER2 positive early breast cancer clinicaltrials.gov\/ct2\/show\/NCT02162667"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD013539.pub2-BIB0155|cit155","doi-asserted-by":"publisher","first-page":"v63","DOI":"10.1093\/annonc\/mdz240.016","article-title":"3-year follow-up of a phase III comparing the efficacy and safety of neoadjuvant and adjuvant and its biosimilar CT-P6 in HER2 positive early breast cancer (EBC)","volume":"30","author":"Stebbing","year":"2019","journal-title":"Annals of Oncology"},{"issue":"7","key":"10.1002\/14651858.CD013539.pub2-BIB0156|cit156","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/S1470-2045(17)30434-5","article-title":"CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial","volume":"18","author":"Stebbing","year":"2017","journal-title":"Lancet Oncology"},{"issue":"Suppl 15","key":"10.1002\/14651858.CD013539.pub2-BIB0157|cit157","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1200\/JCO.2017.35.15_suppl.510","article-title":"Double-blind, randomized phase III study to compare the efficacy and safety of CT-P6, trastuzumab biosimilar candidate versus trastuzumab as neoadjuvant treatment in HER2 positive early breast cancer (EBC)","volume":"35","author":"Stebbing","year":"2017","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD013539.pub2-BIB0158|cit158","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s10549-021-06240-5","article-title":"Long-term efficacy and safety of CT-P6 versus trastuzumab in patients with HER2-positive early breast cancer: final results from a randomized phase III trial","volume":"188","author":"Stebbing","year":"2021","journal-title":"Breast Cancer Research and Treatment"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD013539.pub2-BIB0159|cit159","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1200\/JCO.2018.36.15_suppl.591","article-title":"Pharmacokinetics of CT-P6 and reference trastuzumab by clinical factors in patients with HER2 positive early-stage breast cancer (EBC)","volume":"36","author":"Stebbing","year":"2018","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013539.pub2-BIB0160|cit160","first-page":"S108","article-title":"Phae I\/IIB clinical trial comparing PK and safety of trastuzumab and its biosimilar candidate CT-P6","volume":"22","author":"Im","year":"2013","journal-title":"Breast"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0161|cit161","unstructured":"Evaluate safety, efficacy and pharmacokinetics (compare) clinicaltrials.gov\/ct2\/show\/NCT01084863"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0162|cit162","unstructured":"Clinical study protocol. A randomized, double-blind, parallel group, phase III trial to compare the efficacy, safety, and immunogenicity of TX05 with Herceptin\u00ae in subjects with HER2 positive early breast cancer Tanvex Biologics Corp Protocol TX05-03 Amendment 1 80"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0163|cit163","doi-asserted-by":"publisher","first-page":"S419","DOI":"10.1016\/j.annonc.2021.08.418","article-title":"137P Trial comparing the safety, efficacy and immunogenicity of trastuzumab biosimilar candidate (TX05) with originator trastuzumab in HER2+ early breast cancer","volume":"32","author":"Krivorotko","year":"2021","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0164|cit164","unstructured":"A randomized, double-blind, parallel-group, phase III trial to compare the efficacy, safety, and immunogenicity of TX05 with Herceptin\u00ae in subjects with HER2 positive early breast cancer clinicaltrials.gov\/ct2\/show\/NCT03556358"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0165|cit165","unstructured":"Extension study to provide adjuvant treatment following neoadjuvant treatment and surgical resection in protocol TX05-03 clinicaltrials.gov\/ct2\/show\/NCT04109391"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0166|cit166","unstructured":"European Medicines Agency Assessment report of Trazimera https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/trazimera-epar-public-assessment-report_en.pdf"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD013539.pub2-BIB0167|cit167","doi-asserted-by":"publisher","first-page":"v43","DOI":"10.1093\/annonc\/mdx362.005","article-title":"A randomized, double-blind study of PF-05280014 (a potential biosimilar) vs trastuzumab, both given with docetaxel (D) and carboplatin (C), as neoadjuvant treatment for operable human epidermal growth factor receptor 2-positive (HER2+) breast cancer","volume":"28","author":"Lammers","year":"2017","journal-title":"Annals of Oncology"},{"issue":"3","key":"10.1002\/14651858.CD013539.pub2-BIB0168|cit168","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/s41416-018-0147-1","article-title":"Neoadjuvant PF-05280014 (a potential trastuzumab biosimilar) versus trastuzumab for operable HER2+ breast cancer","volume":"119","author":"Lammers","year":"2018","journal-title":"British Journal of Cancer"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0169|cit169","unstructured":"A study of PF-05280014 or trastuzumab plus Taxotere and carboplatin In HER2 positive breast cancer in the neoadjuvant setting (REFLECTIONS B327-04) clinicaltrials.gov\/ct2\/show\/NCT02187744"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0170|cit170","unstructured":"A multicenter, double-blind, randomized, parallel-group, active-controlled, phase III study to evaluate the efficacy, safety, immunogenicity and pharmacokinetics of BP02 (trastuzumab) in comparison with Herceptin\u00ae-EU in patients with HERr2-positive metastatic breast cancer (MBC) ctri.nic.in\/Clinicaltrials\/pmaindet2.php?EncHid=Mzk3MDI=&Enc=&userName=CTRI\/2020\/04\/024456"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD013539.pub2-BIB0171|cit171","doi-asserted-by":"publisher","first-page":"S1491","DOI":"10.1016\/j.annonc.2023.10.201","article-title":"Efficacy and safety of trastuzumab biosimilar in HER2+ metastatic breast cancer: a multicenter phase III study","volume":"34","author":"Mohan","year":"2023","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0172|cit172","unstructured":"Comparing efficacy and safety of AryoGen pharmed biosimilar trastuzumab (AryoTrust) versus Herceptin\u00ae in breast cancer clinicaltrials.gov\/ct2\/show\/NCT03425656"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0173|cit173","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s40360-022-00599-x","article-title":"A randomized, double-blind, phase III, non-inferiority clinical trial comparing the efficacy and safety of TA4415V (a proposed trastuzumab biosimilar) and Herceptin (trastuzumab reference product) in HER2-positive early-stage breast cancer patients","volume":"23","author":"Nodehi","year":"2022","journal-title":"BMC Pharmacology and Toxicology"},{"issue":"1","key":"10.1002\/14651858.CD013539.pub2-BIB0174|cit174","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s00280-019-03850-1","article-title":"Population pharmacokinetics of PF-05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin\u00ae) in patients with HER2-positive metastatic breast cancer","volume":"84","author":"Chen","year":"2019","journal-title":"Cancer Chemotherapy and Pharmacology"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0175|cit175","unstructured":"European Medicines Agency Assessment report of Trazimera https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/trazimera-epar-public-assessment-report_en.pdf"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD013539.pub2-BIB0176|cit176","doi-asserted-by":"publisher","first-page":"P1","DOI":"10.1158\/1538-7445.SABCS19-P1-18-08","article-title":"P1-18-08: Trazimera (a trastuzumab biosimilar) in HER2-positive metastatic breast cancer: long-term safety and overall survival data","volume":"80","author":"Li","year":"2020","journal-title":"Cancer Research"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0177|cit177","unstructured":"A study of PF-05280014 [trastuzumab-Pfizer] or Herceptin [trastuzumab-EU] plus paclitaxel in HER2 positive first line metastatic breast cancer treatment (REFLECTIONS B327-02) clinicaltrials.gov\/ct2\/show\/NCT01989676"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD013539.pub2-BIB0178|cit178","doi-asserted-by":"publisher","first-page":"v74","DOI":"10.1093\/annonc\/mdx365.001a","article-title":"A randomized double-blind study of PF-05280014 (a potential trastuzumab biosimilar) vs trastuzumab, both in combination with paclitaxel, as first-line treatment for HER2-positive metastatic breast cancer","volume":"28","author":"Pegram","year":"2017","journal-title":"Annals of Oncology"},{"issue":"2","key":"10.1002\/14651858.CD013539.pub2-BIB0179|cit179","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/s41416-018-0340-2","article-title":"PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind study","volume":"120","author":"Pegram","year":"2019","journal-title":"British Journal of Cancer"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD013539.pub2-BIB0180|cit180","doi-asserted-by":"publisher","first-page":"viii69","DOI":"10.1093\/annonc\/mdy270.212","article-title":"Subgroup analyses of efficacy from a phase III study comparing SB3 (trastuzumab biosimilar) with reference trastuzumab in early breast cancer patients","volume":"29","author":"Castan","year":"2018","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0181|cit181","unstructured":"A long-term follow-up study for cardiac safety in the patients with HER2 positive early or locally advanced breast cancer who have completed the SB3-G31-BC clinicaltrialsregister.eu\/ctr-search\/trial\/2015-005663-17\/results"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0182|cit182","unstructured":"A phase III randomised, double-blind, parallel group, multicentre study to compare the efficacy, safety, pharmacokinetics and immunogenicity between SB3 (proposed trastuzumab biosimilar) and Herceptin\u00ae in women with newly diagnosed HER2 positive early or locally advanced breast cancer in neoadjuvant setting clinicaltrialsregister.eu\/ctr-search\/search?query=EUCTR2013-004172-35-PL"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0183|cit183","unstructured":"A study to compare the effect of SB3 and Herceptin\u00ae in women with breast cancer clinicaltrials.gov\/ct2\/show\/NCT02149524"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD013539.pub2-BIB0184|cit184","doi-asserted-by":"publisher","first-page":"P6","DOI":"10.1158\/1538-7445.SABCS18-P6-17-09","article-title":"Abstract P6-17-09: event-free survival by ADCC status from a follow-up study comparing SB3 (trastuzumab biosimilar) with reference trastuzumab for HER2 positive breast cancer in neoadjuvant setting","volume":"79","author":"Pegram","year":"2019","journal-title":"Cancer Research"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0185|cit185","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ejca.2018.01.072","article-title":"A phase III study comparing SB3 (a proposed trastuzumab biosimilar) and trastuzumab reference product in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment: final safety, immunogenicity and survival results","volume":"93","author":"Pivot","year":"2018","journal-title":"European Journal of Cancer"},{"issue":"10","key":"10.1002\/14651858.CD013539.pub2-BIB0186|cit186","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1200\/JCO.2017.74.0126","article-title":"Phase III, randomized, double-blind study comparing the efficacy, safety, and immunogenicity of SB3 (trastuzumab biosimilar) and reference trastuzumab in patients treated with neoadjuvant therapy for human epidermal growth factor receptor 2-positive early","volume":"36","author":"Pivot","year":"2018","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl 15","key":"10.1002\/14651858.CD013539.pub2-BIB0187|cit187","doi-asserted-by":"publisher","first-page":"e12631","DOI":"10.1200\/JCO.2018.36.15_suppl.e12631","article-title":"Additional one-year follow-up study to evaluate safety and survival in patients who have completed neoadjuvant-adjuvant treatment with SB3 (trastuzumab biosimilar) or reference trastuzumab in HER2-positive early or locally advanced breast cancer","volume":"36","author":"Pivot","year":"2018","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0188|cit188","doi-asserted-by":"publisher","first-page":"v43","DOI":"10.1093\/annonc\/mdx362.004","article-title":"One-year safety, immunogenicity, and survival results from a phase III study comparing SB3 (a proposed trastuzumab biosimilar) and originator trastuzumab in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment","volume":"28","author":"Pivot","year":"2017","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0189|cit189","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2019.07.015","article-title":"Three-year follow-up from a phase 3 study of SB3 (a trastuzumab biosimilar) versus reference trastuzumab in the neoadjuvant setting for human epidermal growth factor receptor 2-positive breast cancer","volume":"120","author":"Pivot","year":"2019","journal-title":"European Journal of Cancer"},{"issue":"Suppl 15","key":"10.1002\/14651858.CD013539.pub2-BIB0190|cit190","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1200\/JCO.2017.35.15_suppl.509","article-title":"A randomized, double-blind, phase III study comparing SB3 (trastuzumab biosimilar) with originator trastuzumab in patients treated by neoadjuvant therapy for HER2-positive early breast cancer","volume":"35","author":"Pivot","year":"2017","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0191|cit191","unstructured":"A phase III trial to compare the efficacy, safety and pharmacokinetics of HD201 to Herceptin\u00ae in HER2+ early breast cancer patients clinicaltrials.gov\/ct2\/show\/NCT03013504"},{"issue":"8","key":"10.1002\/14651858.CD013539.pub2-BIB0192|cit192","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1001\/jamaoncol.2021.8171","article-title":"Efficacy of HD201 vs referent trastuzumab in patients with ERBB2-positive breast cancer treated in the neoadjuvant setting: a multicenter phase 3 randomized clinical trial","volume":"1","author":"Pivot","year":"2022","journal-title":"JAMA Oncology"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0193|cit193","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s12885-023-10574-2","article-title":"Final analysis of the phase 3 randomized clinical trial comparing HD201 vs. referent trastuzumab in patients with ERBB2-positive breast cancer treated in the neoadjuvant setting","volume":"23","author":"Pivot","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0194|cit194","unstructured":"A randomized, double-blind, multi-centre, parallel group study comparing two humanized monoclonal antibodies that target HER2 receptors in combination with weekly paclitaxel administered as first-line treatment in patients with HER2-positive metastatic breast cancer (phase 1\/3) ctri.nic.in\/Clinicaltrials\/pmaindet2.php?EncHid=MTI1MTU=&Enc=&userName=CTRI\/2015\/08\/006085"},{"issue":"10","key":"10.1002\/14651858.CD013539.pub2-BIB0195|cit195","doi-asserted-by":"publisher","first-page":"e2200328","DOI":"10.1200\/GO.22.00328","article-title":"Efficacy, safety, pharmacokinetics, and immunogenicity of DRL-trastuzumab versus Herceptin in human epidermal growth factor receptor 2-positive metastatic breast cancer: a randomized controlled trial","volume":"10","author":"Reddy","year":"2024","journal-title":"JCO Global Oncology"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0196|cit196","unstructured":"European Medicines Agency Assessment report of ogivri https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/ogivri-epar-public-assessment-report_en.pdf"},{"issue":"Suppl 15","key":"10.1002\/14651858.CD013539.pub2-BIB0197|cit197","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1200\/JCO.2018.36.15_suppl.110","article-title":"Biosimilar trastuzumab-dkst monotherapy versus trastuzumab monotherapy after combination therapy: toxicity, efficacy, and immunogenicity from the phase 3 Heritage trial","volume":"36","author":"Manikhas","year":"2018","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0198|cit198","unstructured":"A multicenter, double-blind, randomized, parallel-group, phase III study of the efficacy and safety of Hercules plus taxane versus Herceptin\u00ae plus taxane as first line therapy in patients with HER2-positive metastatic breast cancer clinicaltrials.gov\/ct2\/show\/NCT02472964"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0199|cit199","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/S0959-8049(17)30216-2","article-title":"HERITAGE: a phase III safety and efficacy trial of the proposed trastuzumab biosimilar Myl-1401O versus Herceptin","volume":"72","author":"Rugo","year":"2017","journal-title":"European Journal of Cancer"},{"issue":"1","key":"10.1002\/14651858.CD013539.pub2-BIB0200|cit200","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1001\/jama.2016.18305","article-title":"Effect of a proposed trastuzumab biosimilar compared with trastuzumab on overall response rate in patients with ERBB2 (HER2)-positive metastatic breast cancer","volume":"317","author":"Rugo","year":"2017","journal-title":"JAMA"},{"issue":"Suppl 18","key":"10.1002\/14651858.CD013539.pub2-BIB0201|cit201","doi-asserted-by":"publisher","first-page":"LBA503","DOI":"10.1200\/JCO.2016.34.18_suppl.LBA503","article-title":"Heritage: a phase III safety and efficacy trial of the proposed trastuzumab biosimilar Myl-1401O versus Herceptin","volume":"34","author":"Rugo","year":"2016","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0202|cit202","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.breast.2021.03.009","article-title":"Correlation between week 24 trastuzumab-dkst response and week 48 progression-free survival: the HERITAGE trial","volume":"58","author":"Rugo","year":"2021","journal-title":"Breast (Edinburgh, Scotland)"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0203|cit203","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s10549-021-06197-5","article-title":"Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer","volume":"188","author":"Rugo","year":"2021","journal-title":"Breast Cancer Research and Treatment"},{"issue":"Suppl 15","key":"10.1002\/14651858.CD013539.pub2-BIB0204|cit204","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1200\/JCO.2019.37.15_suppl.1021","article-title":"Biosimilar trastuzumab-dkst monotherapy versus trastuzumab monotherapy after combination therapy: final overall survival (OS) from the phase III HERITAGE Trial","volume":"37","author":"Waller","year":"2019","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0205|cit205","unstructured":"A randomized, double-blind, phase 3 study evaluating the efficacy and safety of Abp 980 compared with trastuzumab in subjects with Her2 positive early breast cancer clinicaltrialsregister.eu\/ctr-search\/search?query=2012-004319-29"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0206|cit206","unstructured":"European Medicines Agency Assessment report of kanjinti https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/kanjinti-epar-public-assessment-report_en.pdf"},{"issue":"3","key":"10.1002\/14651858.CD013539.pub2-BIB0207|cit207","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s40264-019-00886-3","article-title":"Cardiac safety of the trastuzumab biosimilar ABP 980 in women with HER2-positive early breast cancer in the randomized, double-blind, active-controlled LILAC study","volume":"43","author":"Colleoni","year":"2020","journal-title":"Drug Safety"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD013539.pub2-BIB0208|cit208","doi-asserted-by":"publisher","first-page":"PD3","DOI":"10.1158\/1538-7445.SABCS17-PD3-10","article-title":"PD3-10: safety results from a randomized, double-blind, phase 3 study of ABP 980 compared with trastuzumab in patients with breast cancer","volume":"78","author":"Demetriou","year":"2018","journal-title":"Cancer Research"},{"issue":"Suppl 15","key":"10.1002\/14651858.CD013539.pub2-BIB0209|cit209","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1200\/JCO.2018.36.15_suppl.583","article-title":"Efficacy analyses of central laboratory pCR results from the LILAC study comparing the biosimilar ABP 980 and trastuzumab","volume":"36","author":"Tomasevic","year":"2018","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0210|cit210","doi-asserted-by":"publisher","first-page":"S103","DOI":"10.1016\/S0959-8049(18)30537-9","article-title":"365 (PB-160) \u2013 clinical comparison of the biosimilar ABP 980 and trastuzumab in early breast cancer: results of the phase 3 LILAC study and justification for extrapolation across approved trastuzumab indications","volume":"92","author":"Kolberg","year":"2018","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0211|cit211","unstructured":"Efficacy and safety study of ABP980 compared with trastuzumab in women with HER2-positive early breast cancer (Lilac) clinicaltrials.gov\/ct2\/show\/NCT01901146"},{"issue":"7","key":"10.1002\/14651858.CD013539.pub2-BIB0212|cit212","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/S1470-2045(18)30241-9","article-title":"Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial","volume":"19","author":"Minckwitz","year":"2018","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0213|cit213","doi-asserted-by":"publisher","first-page":"v44","DOI":"10.1093\/annonc\/mdx362.002","article-title":"Efficacy and safety of biosimilar ABP 980 compared with trastuzumab in HER2 positive early breast cancer","volume":"28","author":"Minckwitz","year":"2017","journal-title":"Annals of Oncology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD013539.pub2-BIB0214|cit214","doi-asserted-by":"publisher","first-page":"P5","DOI":"10.1158\/1538-7445.SABCS17-P5-20-13","article-title":"P5-20-13: biosimilar ABP 980 in patients with early breast cancer: results of single switch from trastuzumab to ABP 980","volume":"78","author":"Minckwitz","year":"2018","journal-title":"Cancer Research"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0215|cit215","unstructured":"European Medicines Agency Assessment report of zercepac https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/zercepac"},{"issue":"Suppl 9","key":"10.1002\/14651858.CD013539.pub2-BIB0216|cit216","doi-asserted-by":"publisher","first-page":"ix185","DOI":"10.1093\/annonc\/mdz446.005","article-title":"First China-manufactured trastuzumab biosimilar HLX02 global phase III trial met primary endpoint in breast cancer","volume":"30","author":"Xu","year":"2019","journal-title":"Annals of Oncology"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD013539.pub2-BIB0217|cit217","doi-asserted-by":"publisher","first-page":"v106","DOI":"10.1093\/annonc\/mdz242","article-title":"Efficacy and safety of first China-manufactured trastuzumab biosimilar HLX02 for metastatic breast cancer: a phase III trial","volume":"30","author":"Xu","year":"2019","journal-title":"Annals of Oncology"},{"issue":"3","key":"10.1002\/14651858.CD013539.pub2-BIB0218|cit218","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s40259-021-00475-w","article-title":"Efficacy, safety, and immunogenicity of HLX02 compared with reference trastuzumab in patients with recurrent or metastatic HER2-positive breast cancer: a randomized phase III equivalence trial","volume":"35","author":"Xu","year":"2021","journal-title":"BioDrugs"},{"issue":"1","key":"10.1002\/14651858.CD013539.pub2-BIB0219|cit219","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.1016\/S1470-2045(16)30638-6","article-title":"Trastuzumab biosimilar shows potential for breast cancer","volume":"18","author":"Baker","year":"2017","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0220|cit220","unstructured":"European Medicines Agency European public assessment report (EPAR): Herwenda https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/herwenda-epar-public-assessment-report_en.pdf"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0221|cit221","doi-asserted-by":"crossref","unstructured":"Grohmann-Izay B Dzagnidze G Llin\u00e1s N P2-13-17. A phase III, randomized, multicenter, double-blind study to compare efficacy and safety of EG12014 (EirGenix trastuzumab) with Herceptin as neoadjuvant treatment in combination with anthracycline\/paclitaxel-based systemic therapy in patients with HER2-positive early breast cancer \u2013 a multinational phase III study conducted during the COVID-19 pandemic San Antonio Breast Cancer Symposium; 2021 December 7-10; San Antonio (TX)","DOI":"10.1158\/1538-7445.SABCS21-P2-13-17"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0222|cit222","unstructured":"Efficacy and safety study of EG12014 compared with Herceptin in subjects with HER2 positive early breast cancer clinicaltrials.gov\/ct2\/show\/NCT03433313"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0223|cit223","unstructured":"A long-term follow-up study for cardiac safety in the patients with HER2 (+) breast cancer who have completed the SB3-G31-BC clinicaltrials.gov\/ct2\/show\/NCT02771795"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0224|cit224","unstructured":"A study to evaluate safety, tolerability, PK and PD of HLX01 in patients with CD20-positive B-cell lymphomas clinicaltrials.gov\/ct2\/show\/record\/NCT03218072"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0225|cit225","unstructured":"Pharmacokinetic equivalence and safety study of RPH-001 and Avastin\u00ae clinicaltrials.gov\/ct2\/show\/record\/NCT03659305"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0226|cit226","unstructured":"A study to compare the bioequivalence and safety of JHL1101 and rituximab in CD20 positive B cell lymphoma patients clinicaltrials.gov\/ct2\/show\/record\/NCT03670888"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0227|cit227","unstructured":"A study to compare the efficacy and safety of JHL1101 versus rituximab in patients with previously untreated diffuse large B-cell lymphoma (DLBCL) clinicaltrials.gov\/ct2\/show\/NCT03670901"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0228|cit228","unstructured":"Efficacy and safety of trastuzumab biosimilar (Herzuma\u00ae) plus treatment of physician's choice (TPC) in patients with HER-2 positive metastatic breast cancer clinicaltrials.gov\/ct2\/show\/record\/NCT03755141"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0229|cit229","unstructured":"Trastuzumab biosimilar (Samfenet\u00ae) plus treatment of physician's choice (TPC) in patients with HER2-positive solid tumor clinicaltrials.gov\/ct2\/show\/NCT04215159"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0230|cit230","unstructured":"Study of ramucirumab, trastuzumab and paclitaxel in patients with HER2-positive recurrent\/metastatic gastric cancer (HER-RAM Study) clinicaltrials.gov\/ct2\/show\/record\/NCT04888663"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0231|cit231","unstructured":"Evaluaci\u00f3n del efecto y la seguridad del RituxCIM (Rituximab biosimilar) en pacientes con Linfoma no Hodgkin de c\u00e9lulas B indolente refractario o en reca\u00edda rpcec.sld.cu\/ensayos\/RPCEC00000174-Sp"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0232|cit232","unstructured":"Pharmacokinetics and safety of 1B8 vs MabThera evaluation, both in combination with CHOP chemotherapy in newly diagnosed patients diffuse large B-cell lymphoma, CD 20+ rpcec.sld.cu\/en\/trials\/RPCEC00000216-En"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0233|cit233","unstructured":"Safety and effectiveness of Cimabior\u00ae in patients with CD20-positive B-cell non-Hodgkin lymphoma rpcec.sld.cu\/en\/trials\/RPCEC00000251-En\/revisions\/3798\/view"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0234|cit234","unstructured":"Study to compare the efficacy and safety of GBR 200 (similar biologic of trastuzumab) versus innovator trastuzumab both when given in combination with paclitaxel in patients diagnosed with HER2 positive metastatic breast cancer ctri.nic.in\/Clinicaltrials\/pmaindet2.php?trialid=17718&EncHid=&userName=CTRI\/2017\/02\/007892"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0235|cit235","unstructured":"A phase II clinical trial examining trastuzumab biosimilar (CT-P6) and chemotherapy (oxaliplatin +S-1 or oxaliplatin + capecitabine) for treatment of HER2-positive advanced\/recurrent gastric cancer previously untreated with chemotherapy (TROX study) jrct.niph.go.jp\/en-latest-detail\/jRCTs071190007"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0236|cit236","unstructured":"Efficacy-safety-immunogenicity study of CBT124 & EU-sourced Avastin\u00ae in stage 4 NSCLC clinicaltrials.gov\/ct2\/show\/NCT02879097"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0237|cit237","unstructured":"A trial to compare the efficacy, safety, pharmacokinetics and immunogenecity of HD204 to Avastin\u00ae in advanced non-squamous non-small cell lung cancer patients clinicaltrials.gov\/show\/NCT03390686"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0238|cit238","unstructured":"A study of SIBP-01 or CN-trastuzumab plus docetaxel and carboplatin In HER2 positive breast cancer clinicaltrials.gov\/ct2\/show\/NCT03989037"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0239|cit239","unstructured":"A study comparing SIBP-02 and rituximab combination with CHOP in previously untreated subjects with CD20+ DLBCL clinicaltrials.gov\/ct2\/show\/record\/NCT04361279"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0240|cit240","unstructured":"A study comparing the efficacy and safety between H-CHOP and R-CHOP in untreated CD20-positive diffuse large B-cell lymphoma patients clinicaltrials.gov\/ct2\/show\/NCT05040906"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0241|cit241","unstructured":"To compare the efficacy and safety of BP102 vs. Avastin\u00ae in combination with paclitaxel\/carboplatin in first-line treatment of advanced or relapsed NSCLC clinicaltrials.gov\/ct2\/show\/record\/NCT05169801"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0242|cit242","unstructured":"Clinical trial to assess pharmacokinetic parameters and safety of NNG-TMAB (trastuzumab) on recurrent or metastatic breast cancer patients clinicaltrials.gov\/ct2\/show\/record\/NCT05301530"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0243|cit243","unstructured":"A safety and efficacy study of bevacizumab, paclitaxel, carboplatin compared to Avastin\u00ae in non-small cell lung cancer clinicaltrials.gov\/ct2\/show\/NCT05654454"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0244|cit244","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.jclinepi.2020.05.034","article-title":"Meta-analysis of noninferiority and equivalence trials: ignoring trial design leads to differing and possibly misleading conclusions","volume":"127","author":"Acuna","year":"2020","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0245|cit245","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1186\/s12885-022-09895-5","article-title":"Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2- positive breast cancer patients: a randomized, phase III, equivalency clinical trial","volume":"22","author":"Allahyari","journal-title":"BMC Cancer"},{"issue":"11","key":"10.1002\/14651858.CD013539.pub2-BIB0246|cit246","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1080\/17460441.2020.1796627","article-title":"Explaining biosimilars and how reverse engineering plays a critical role in their development","volume":"15","author":"Bellinvia","year":"2020","journal-title":"Expert Opinion on Drug Discovery"},{"issue":"5","key":"10.1002\/14651858.CD013539.pub2-BIB0247|cit247","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.clinthera.2017.03.014","article-title":"Comparing originator biologics and biosimilars: a review of the relevant issues","volume":"39","author":"Blandizi","year":"2017","journal-title":"Clinical Therapeutics"},{"issue":"4","key":"10.1002\/14651858.CD013539.pub2-BIB0248|cit248","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1001\/jamaoncol.2021.7230","article-title":"Characteristics of clinical trials evaluating biosimilars in the treatment of cancer: a systematic review and meta-analysis","volume":"8","author":"Bloomfield","year":"2022","journal-title":"JAMA Oncology"},{"issue":"3","key":"10.1002\/14651858.CD013539.pub2-BIB0249|cit249","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global Cancer Statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA: A Cancer Journal for Clinicians"},{"issue":"5","key":"10.1002\/14651858.CD013539.pub2-BIB0250|cit250","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s00280-020-04156-3","article-title":"Comparative efficacy and safety of trastuzumab biosimilars to the reference drug: a systematic review and meta-analysis of randomized clinical trials","volume":"86","author":"Cargnin","year":"2020","journal-title":"Cancer Chemotherapy and Pharmacology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD013539.pub2-BIB0251|cit251","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1097\/00001813-200211002-00002","article-title":"Mechanism of action of rituximab","volume":"13","author":"Cerny","year":"2002","journal-title":"Anti-cancer Drugs"},{"issue":"5","key":"10.1002\/14651858.CD013539.pub2-BIB0252|cit252","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"Journal of Clinical Oncology"},{"issue":"27","key":"10.1002\/14651858.CD013539.pub2-BIB0253|cit253","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"Journal of Clinical Oncology"},{"issue":"12","key":"10.1002\/14651858.CD013539.pub2-BIB0254|cit254","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1007\/s12325-016-0431-5","article-title":"Awareness, knowledge, and perceptions of biosimilars among specialty physicians","volume":"33","author":"Cohen","year":"2016","journal-title":"Advances in Therapy"},{"issue":"1","key":"10.1002\/14651858.CD013539.pub2-BIB0255|cit255","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s10549-019-05227-7","article-title":"Randomised clinical endpoint studies for trastuzumab biosimilars: a systematic review","volume":"176","author":"Coory","year":"2019","journal-title":"Breast Cancer Research and Treatment"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0256|cit256","unstructured":"Covidence Veritas Health Innovation 2022"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0257|cit257","unstructured":"Deeks JJ Higgins JP Altman DG Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021 Available from training.cochrane.org\/handbook\/archive\/v6.2"},{"issue":"7109","key":"10.1002\/14651858.CD013539.pub2-BIB0258|cit258","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"British Medical Journal"},{"issue":"2","key":"10.1002\/14651858.CD013539.pub2-BIB0259|cit259","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0260|cit260","unstructured":"European Medicines Agency Guideline on similar biological medicinal products containing monoclonal antibodies \u2013 non-clinical and clinical issues https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-similar-biological-medicinal-products-containing-monoclonal-antibodies-non-clinical_en.pdf"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0261|cit261","unstructured":"European Medicines Agency Guideline on similar biological medicinal products https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-similar-biological-medicinal-products-rev1_en.pdf"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0262|cit262","unstructured":"European Medicines Agency Biosimilars in the EU \u2013 information guide for healthcare professionals https:\/\/www.ema.europa.eu\/en\/documents\/leaflet\/biosimilars-eu-information-guide-healthcare-professionals_en.pdf"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0263|cit263","unstructured":"European Medicines Agency European public assessment report (EPAR): ontruzant https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/ontruzant-epar-public-assessment-report_en-0.pdf"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0264|cit264","unstructured":"European Medicines Agency European public assessment report (EPAR): rixathon https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/rixathon-epar-public-assessment-report_en.pdf"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0265|cit265","unstructured":"European Medicines Agency Guideline on immunogenicity assessment of therapeutic proteins https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-immunogenicity-assessment-therapeutic-proteins-revision-1_en.pdf"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0266|cit266","unstructured":"European Medicines Agency List of medicines under additional monitoring https:\/\/www.ema.europa.eu\/en\/human-regulatory\/post-authorisation\/pharmacovigilance\/medicines-under-additional-monitoring\/list-medicines-under-additional-monitoring"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0267|cit267","unstructured":"European Medicines Agency European public assessment report (EPAR): blitzima https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/blitzima"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0268|cit268","unstructured":"European Medicines Agency European public assessment report (EPAR): mvasi https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/mvasi"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0269|cit269","unstructured":"European Medicines Agency Medicines search: rituximab \u2013 biosimilar https:\/\/www.ema.europa.eu\/en\/search"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0270|cit270","unstructured":"European Medicines Agency Medicines search: trastuzumab \u2013 biosimilar https:\/\/www.ema.europa.eu\/en\/search"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0271|cit271","unstructured":"European Medicines Agency Medicines search: bevacizumab \u2013 biosimilar https:\/\/www.ema.europa.eu\/en\/search"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0272|cit272","unstructured":"Scientific considerations in demonstrating biosimilarity to a reference product \u2013 guidance for industry https:\/\/www.fda.gov\/media\/82647\/download"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0273|cit273","unstructured":"FDA approves first biosimilar for the treatment of certain breast and stomach cancers https:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm587378.htm"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0274|cit274","unstructured":"Mvasi approval letter https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/761028Orig1s000Approv.pdf"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0275|cit275","unstructured":"Summary review: ogivri https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/761074Orig1s000SumR.pdf"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0276|cit276","unstructured":"Summary review: Truxima https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/761088Orig1s000SumR.pdf"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0277|cit277","unstructured":"Clinical trial endpoints for the approval of cancer drugs and biologics https:\/\/www.fda.gov\/media\/71195\/download"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0278|cit278","unstructured":"Hematology\/oncology (cancer) approvals & safety notifications https:\/\/www.fda.gov\/Drugs\/InformationOnDrugs\/ApprovedDrugs\/ucm279174.htm"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0279|cit279","unstructured":"Immunogenicity testing of therapeutic protein products \u2013 developing and validating assays for anti-drug antibody detection https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/immunogenicity-testing-therapeutic-protein-products-developing-and-validating-assays-anti-drug"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0280|cit280","unstructured":"Pathological complete response in neoadjuvant treatment of high-risk early-stage breast-cancer: use as an endpoint to support accelerated approval https:\/\/www.fda.gov\/media\/83507\/download"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0281|cit281","unstructured":"Purple book database of licensed biological products: Rituxan https:\/\/purplebooksearch.fda.gov\/results?query=rituximab&title=Rituxan"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0282|cit282","unstructured":"Purple book database of licensed biological products: trastuzumab https:\/\/purplebooksearch.fda.gov\/results?query=trastuzumab&title=Herceptin"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0283|cit283","unstructured":"Purple book database of licensed biological products: bevacizumab https:\/\/purplebooksearch.fda.gov\/results?query=bevacizumab&title=Avastin"},{"issue":"1","key":"10.1002\/14651858.CD013539.pub2-BIB0284|cit284","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.jclinepi.2005.06.006","article-title":"Imputing missing standard deviations in meta-analyses can provide accurate results","volume":"59","author":"Furukawa","year":"2006","journal-title":"Journal of Clinical Epidemiology"},{"issue":"1","key":"10.1002\/14651858.CD013539.pub2-BIB0285|cit285","doi-asserted-by":"publisher","first-page":"24","DOI":"10.5639\/gabij.2019.0801.003","article-title":"Patent expiry dates for biologicals: 2018 update","volume":"8","year":"2019","journal-title":"Generics and Biosimilars Initiative Journal"},{"issue":"1","key":"10.1002\/14651858.CD013539.pub2-BIB0286|cit286","doi-asserted-by":"publisher","first-page":"35","DOI":"10.5639\/gabij.2018.0701.008","article-title":"Top developments in biosimilars during 2017","volume":"7","year":"2018","journal-title":"Generics and Biosimilars Initiative Journal"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0287|cit287","unstructured":"Biosimilars approved in Europe https:\/\/www.gabionline.net\/biosimilars\/general\/biosimilars-approved-in-europe"},{"issue":"8","key":"10.1002\/14651858.CD013539.pub2-BIB0288|cit288","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.3174\/ajnr.A2619","article-title":"Trastuzumab (Herceptin)","volume":"32","author":"Gemmete","year":"2011","journal-title":"American Journal of Neuroradiology"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0289|cit289","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime) 2022"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0290|cit290","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/3762864","article-title":"Biosimilars have arrived: rituximab","volume":"2018","author":"Greenwald","year":"2018","journal-title":"Arthritis"},{"issue":"1","key":"10.1002\/14651858.CD013539.pub2-BIB0291|cit291","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.tibtech.2018.05.014","article-title":"The increasingly human and profitable monoclonal antibody market","volume":"37","author":"Grilo","year":"2019","journal-title":"Trends in Biotechnology"},{"issue":"4","key":"10.1002\/14651858.CD013539.pub2-BIB0292|cit292","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jclinepi.2010.09.012","article-title":"GRADE guidelines: 2. Framing the question and deciding on important outcomes","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"12","key":"10.1002\/14651858.CD013539.pub2-BIB0293|cit293","doi-asserted-by":"publisher","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0294|cit294","unstructured":"Higgins JP Altman DG Sterne JA Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). Cochrane, 2017 Available from training.cochrane.org\/handbook\/archive\/v5.2"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0295|cit295","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3389\/fphar.2020.572569","article-title":"Pharmacoeconomic evaluation of cancer biosimilars worldwide: a systematic review","volume":"11","author":"Yu","year":"2020","journal-title":"Frontiers in Pharmacology"},{"issue":"1","key":"10.1002\/14651858.CD013539.pub2-BIB0296|cit296","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1056\/NEJMra043186","article-title":"Trastuzumab \u2013 mechanism of action and use in clinical practice","volume":"357","author":"Hudis","year":"2007","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0297|cit297","doi-asserted-by":"publisher","first-page":"937","DOI":"10.2147\/PPA.S104891","article-title":"Patient attitudes and understanding about biosimilars: an international cross-sectional survey","volume":"10","author":"Jacobs","year":"2016","journal-title":"Patient Preference and Adherence"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0298|cit298","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s40259-016-0199-9","article-title":"Monoclonal antibody and fusion protein biosimilars across therapeutic areas: a systematic review of published evidence","volume":"30","author":"Jacobs","year":"2016","journal-title":"BioDrugs"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0299|cit299","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40259-016-0207-0","article-title":"Biosimilars for the treatment of cancer: a systematic review of published evidence","volume":"31","author":"Jacobs","year":"2017","journal-title":"BioDrugs"},{"issue":"4","key":"10.1002\/14651858.CD013539.pub2-BIB0300|cit300","doi-asserted-by":"publisher","first-page":"281","DOI":"10.2471\/BLT.17.206284","article-title":"Regulatory evaluation of biosimilars throughout their product life-cycle","volume":"96","author":"Kang","year":"2018","journal-title":"Bulletin of the World Health Organization"},{"issue":"8","key":"10.1002\/14651858.CD013539.pub2-BIB0301|cit301","doi-asserted-by":"publisher","first-page":"e362","DOI":"10.1016\/S2352-3026(17)30120-5","article-title":"Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial","volume":"4","author":"Kim","year":"2017","journal-title":"Lancet Haematology"},{"issue":"6","key":"10.1002\/14651858.CD013539.pub2-BIB0302|cit302","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1185\/03007995.2012.686902","article-title":"Comparability and biosimilarity: considerations for the healthcare provider","volume":"28","author":"Lee","year":"2012","journal-title":"Current Medical Research and Opinion"},{"issue":"5","key":"10.1002\/14651858.CD013539.pub2-BIB0303|cit303","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s40259-019-00376-z","article-title":"Comparative efficacy and safety of biosimilar rituximab and originator rituximab in rheumatoid arthritis and non-Hodgkin's lymphoma: a systematic review and meta-analysis","volume":"33","author":"Lee","year":"2019","journal-title":"BioDrugs"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0304|cit304","unstructured":"Lefebvre C Glanville J Briscoe S Featherstone R Littlewood A Marshall C Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from training.cochrane.org\/handbook\/archive\/v6.3"},{"issue":"1","key":"10.1002\/14651858.CD013539.pub2-BIB0305|cit305","doi-asserted-by":"publisher","first-page":"102","DOI":"10.18553\/jmcp.2019.25.1.102","article-title":"Factors affecting health care provider knowledge and acceptance of biosimilar medicines: a systematic review","volume":"25","author":"Leonard","year":"2019","journal-title":"Journal of Managed Care & Specialty Pharmacy"},{"issue":"6","key":"10.1002\/14651858.CD013539.pub2-BIB0306|cit306","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1080\/08923973.2022.2090956","article-title":"Trastuzumab biosimilars vs trastuzumab originator in the treatment of HER2-positive breast cancer: a systematic review and network meta-analysis","volume":"44","author":"Liu","year":"2022","journal-title":"Immunopharmacology and Immunotoxicology"},{"issue":"21","key":"10.1002\/14651858.CD013539.pub2-BIB0307|cit307","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1056\/NEJMhle1800125","article-title":"Rationale, opportunities, and reality of biosimilar medications","volume":"378","author":"Lyman","year":"2018","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD013539.pub2-BIB0308|cit308","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s40259-017-0218-5","article-title":"Developing the totality of evidence for biosimilars: regulatory considerations and building confidence for the healthcare community","volume":"31","author":"Markus","year":"2017","journal-title":"BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy"},{"issue":"4","key":"10.1002\/14651858.CD013539.pub2-BIB0309|cit309","doi-asserted-by":"publisher","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0310|cit310","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/d41573-021-00079-7","article-title":"FDA approves 100th monoclonal antibody product","volume":"20","author":"Mullard","year":"2021","journal-title":"Nature Reviews Drug Discovery"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0311|cit311","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s40259-023-00576-8","article-title":"Comparative safety profiles of oncology biosimilars: a systematic review and network meta-analysis","volume":"37","author":"Na","year":"2023","journal-title":"BioDrugs"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0312|cit312","unstructured":"Double-blind study to evaluate the PK, efficacy, safety and immunogenicity of MB12 Versus Keytruda\u00ae in stage IV NSCLC clinicaltrials.gov\/study\/NCT05668650"},{"issue":"11","key":"10.1002\/14651858.CD013539.pub2-BIB0313|cit313","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1200\/JCO.2007.15.7438","article-title":"Monoclonal antibodies in cancer therapy: 25 years of progress","volume":"26","author":"Oldham","year":"2008","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0314|cit314","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3389\/fphar.2013.00057","article-title":"Systemic cancer therapy: achievements and challenges that lie ahead","volume":"4","author":"Palumbo","year":"2013","journal-title":"Frontiers in Pharmacology"},{"issue":"24","key":"10.1002\/14651858.CD013539.pub2-BIB0315|cit315","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1002\/(sici)1097-0258(19981230)17:24<2815::aid-sim110>3.0.co;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0316|cit316","doi-asserted-by":"publisher","first-page":"4591","DOI":"10.2147\/CMAR.S164201","article-title":"The role of biosimilars in value-based oncology care","volume":"10","author":"Patel","year":"2018","journal-title":"Cancer Management and Research"},{"issue":"1","key":"10.1002\/14651858.CD013539.pub2-BIB0317|cit317","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1093\/ecco-jcc\/jjw138","article-title":"Patient perspectives on biosimilars: a survey by the European Federation of Crohn's and Ulcerative Colitis Associations","volume":"11","author":"Peyrin-Biroulet","year":"2016","journal-title":"Journal of Crohn's & Colitis"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0318|cit318","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ejca.2018.01.072","article-title":"A phase III study comparing SB3 (a proposed trastuzumab biosimilar) and trastuzumab reference product in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment: final safety, immunogenicity and survival results","volume":"93","author":"Pivot","year":"2018","journal-title":"European Journal of Cancer"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD013539.pub2-BIB0319|cit319","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1053\/j.seminoncol.2014.03.008","article-title":"Biosimilars in oncology: from development to clinical practice","volume":"41","author":"Rak","year":"2014","journal-title":"Seminars in Oncology"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0320|cit320","unstructured":"Review Manager (RevMan) The Cochrane Collaboration 2024"},{"issue":"Suppl 9","key":"10.1002\/14651858.CD013539.pub2-BIB0321|cit321","doi-asserted-by":"publisher","first-page":"24s","DOI":"10.1200\/JOP.2017.025734","article-title":"Biosimilars: implications for clinical practice","volume":"13","author":"Rifkin","year":"2017","journal-title":"Journal of Oncology Practice"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0322|cit322","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.jclinepi.2019.10.014","article-title":"GRADE guidelines 26: informative statements to communicate the findings of systematic reviews of interventions","volume":"119","author":"Santesso","year":"2020","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0323|cit323","doi-asserted-by":"publisher","first-page":"e034183","DOI":"10.1136\/bmjopen-2019-034183","article-title":"Physicians' perceptions of the uptake of biosimilars: a systematic review","volume":"10","author":"Sarnola","year":"2020","journal-title":"BMJ Open"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0324|cit324","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N on behalf of the Cochrane GRADEing Methods Group (formerly Applicability and Recommendations Methods Group) and the Cochrane Statistical Methods Group Chapter 14: Completing 'Summary of findings' tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from training.cochrane.org\/handbook\/archive\/v6.3"},{"issue":"11","key":"10.1002\/14651858.CD013539.pub2-BIB0325|cit325","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1016\/j.clinthera.2006.11.015","article-title":"Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies","volume":"28","author":"Shih","year":"2006","journal-title":"Clinical Therapeutics"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0326|cit326","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.jclinepi.2019.10.015","article-title":"GRADE guidelines 27: how to calculate absolute effects for time-to-event outcomes in summary of findings tables and Evidence Profiles","volume":"118","author":"Skoetz","year":"2020","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0327|cit327","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1002\/jppr.1827","article-title":"Safety and efficacy comparisons of rituximab biosimilars to the reference product in patients with cancer: a systematic meta-analysis review","volume":"52","author":"Song","year":"2022","journal-title":"Journal of Pharmacy Practice and Research"},{"issue":"7","key":"10.1002\/14651858.CD013539.pub2-BIB0328|cit328","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1158\/1078-0432.CCR-18-2702","article-title":"Efficacy and safety of biosimilar ABP 215 compared with bevacizumab in patients with advanced non-small cell lung cancer (MAPLE): a randomized, double-blind, phase 3 study","volume":"25","author":"Thatcher","year":"2019","journal-title":"Clinical Cancer Research"},{"issue":"4","key":"10.1002\/14651858.CD013539.pub2-BIB0329|cit329","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.clbc.2021.11.006","article-title":"Comparison of the efficacy, safety, pharmacokinetic and immunogenicity of UJVIRA (ZRC-3256, trastuzumab emtansine) with the Kadcyla (trastuzumab emtansine) in the treatment of HER2-positive metastatic breast cancer: a randomized, open-label, multicenter study in India","volume":"22","author":"Thungappa","year":"2022","journal-title":"Clinical Breast Cancer"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0330|cit330","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0331|cit331","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.3390\/biomedicines10082045","article-title":"Systematic review on the use of biosimilars of trastuzumab in HER2+ breast cancer","volume":"10","author":"Triantafyllidi","year":"2022","journal-title":"Biomedicines"},{"issue":"12","key":"10.1002\/14651858.CD013539.pub2-BIB0332|cit332","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1007\/s00520-023-08184-6","article-title":"Patients' perspectives on the relevance of biosimilars' outcomes in oncology: qualitative study with nominal group technique","volume":"31","author":"Vecoso","year":"2023","journal-title":"Supportive Care in Cancer"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0333|cit333","doi-asserted-by":"publisher","first-page":"62","DOI":"10.3389\/fonc.2012.00062","article-title":"Trastuzumab: updated mechanisms of action and resistance in breast cancer","volume":"2","author":"Vu","year":"2012","journal-title":"Frontiers in Oncology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD013539.pub2-BIB0334|cit334","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/rheumatology\/kex278","article-title":"The process defines the product: what really matters in biosimilar design and production?","volume":"56","author":"Vulto","year":"2017","journal-title":"Rheumatology"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0335|cit335","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1038\/nbt.4305","article-title":"Biopharmaceutical benchmarks 2018","volume":"36","author":"Walsh","year":"2018","journal-title":"Nature Biotechnology"},{"issue":"6","key":"10.1002\/14651858.CD013539.pub2-BIB0336|cit336","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.cell.2012.02.034","article-title":"Antibody-based immunotherapy of cancer","volume":"148","author":"Weiner","year":"2012","journal-title":"Cell"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0337|cit337","unstructured":"World Health Organization Guidelines on evaluation of similar biotherapeutic products (SBPs) https:\/\/www.who.int\/publications\/m\/item\/sbp-trs-977-Annex-2"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0338|cit338","unstructured":"World Health Organization Guidelines on the quality, safety and efficacy of biotherapeutic protein products prepared by recombinant DNA technology, Annex 4, TRS No 987 https:\/\/www.who.int\/publications\/m\/item\/recombinant-dna-annex-4-trs-no-987"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0339|cit339","unstructured":"World Health Organization Guidelines on procedures and data requirements for changes to approved biotherapeutic products, Annex 3, TRS No 1011 https:\/\/www.who.int\/publications\/m\/item\/approved-biotherapeutics-a3-trs-no-1011"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0340|cit340","unstructured":"World Health Organization WHO questions and answers: similar biotherapeutic products https:\/\/www.who.int\/publications\/m\/item\/who-questions-and-answers-similar-biotherapeutic-products"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0341|cit341","unstructured":"World Health Organization Biotherapeutic products https:\/\/www.who.int\/teams\/health-product-policy-and-standards\/standards-and-specifications\/biotherapeutic-products"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0342|cit342","unstructured":"World Health Organization Cancer https:\/\/www.who.int\/health-topics\/cancer#tab=tab_3"},{"issue":"6","key":"10.1002\/14651858.CD013539.pub2-BIB0343|cit343","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.21037\/tcr-22-71","article-title":"Comparison of efficacy and safety of bevacizumab biosimilar and original bevacizumab in non-squamous non-small cell lung cancer: a systematic review and meta-analysis","volume":"11","author":"Xiao","year":"2022","journal-title":"Translational Cancer Research"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0344|cit344","doi-asserted-by":"publisher","first-page":"880090","DOI":"10.3389\/fphar.2022.880090","article-title":"Efficacy and safety of bevacizumab biosimilars compared with reference biologics in advanced non-small cell lung cancer or metastatic colorectal cancer patients: a network meta-analysis","volume":"13","author":"Xu","year":"2022","journal-title":"Frontiers in Pharmacology"},{"issue":"4","key":"10.1002\/14651858.CD013539.pub2-BIB0345|cit345","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s4025","article-title":"Efficacy and safety of anti-cancer biosimilars compared to reference biologics in oncology: a systematic review and meta-analysis of randomized controlled trials","volume":"33","author":"Yang","year":"2019","journal-title":"BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0346|cit346","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/17588359221130501","article-title":"Efficacy and safety of adding bevacizumab biosimilar or original drug to platinum-based chemotherapy as first-line treatment in patients with advanced NSCLC: a systematic review and meta-analysis","volume":"14","author":"Yang","year":"2022","journal-title":"Therapeutic Advances in Medical Oncology"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0347|cit347","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/jcpt.13799","article-title":"Efficacy and safety of rituximab biosimilars or reference product as first-line treatment in patients with low-tumour-burden follicular lymphoma: a systematic review and meta-analysis","volume":"47","author":"Yang","year":"2022","journal-title":"Journal of Clinical Pharmacy and Therapeutics"},{"key":"10.1002\/14651858.CD013539.pub2-BIB0348|cit348","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jclinepi.2021.03.026","article-title":"GRADE guidelines 32: GRADE offers guidance on choosing targets of GRADE certainty of evidence ratings","volume":"137","author":"Zeng","year":"2021","journal-title":"Journal of Clinical Epidemiology"},{"issue":"2","key":"10.1002\/14651858.CD013539.pub2-BIB0349|cit349","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013539","article-title":"Biosimilar monoclonal antibodies for cancer treatment","author":"Galv\u00e3o","year":"2020","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T03:04:59Z","timestamp":1786590299000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD013539.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Central Editorial Service","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,11,28]]},"references-count":349,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd013539.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,28]]}}}